Nitrogen-containing polycyclic derivative inhibitor as well as preparation method and application thereof

By designing a PRMT5-MTA inhibitor with selective activity on MTAP-deletion cells, the problem of insufficient hematotoxicity and selectivity of existing PRMT5 inhibitors is solved, and effective inhibition and safety improvement of tumor cells is achieved.

CN119060035APending Publication Date: 2024-12-03SHANGHAI HANSOH BIOMEDICAL CO LTD +1
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202410698282.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-14
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing PRMT5 inhibitors have severe hematotoxic side effects in clinical practice and have a small safety window, and are not selective to tumor cells with MTAP deletion, making it difficult to effectively inhibit tumor growth.

Method used

Develop a new PRMT5-MTA selective inhibitor, which is only active on MTAP-deleted cells and has weak inhibition on MTAP wild-type cells. Through the design of specific compound structure, it reduces the impact on normal cells and improves tumors. Selectivity of cells.

Benefits of technology

Effectively inhibit MTAP-deletion tumor cells, reduce toxicity to normal cells, improve treatment safety and effectiveness, and provide a potential new tumor treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004870364020000021
    Figure BDA0004870364020000021
  • Figure BDA0004870364020000081
    Figure BDA0004870364020000081
  • Figure BDA0004870364020000082
    Figure BDA0004870364020000082
Patent Text Reader

Abstract

The invention relates to a nitrogen-containing polycyclic derivative inhibitor as well as a preparation method and application thereof. Particularly, the invention relates to a nitrogen-containing polycyclic compound, a preparation method of the nitrogen-containing polycyclic compound, a pharmaceutical composition containing the nitrogen-containing polycyclic compound and application of the nitrogen-containing polycyclic compound to treatment of cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of drug synthesis, and specifically relates to a nitrogen-containing polycyclic derivative inhibitor and a preparation method and application thereof. Background Art

[0002] Protein arginase methyltransferases (PRMTs) are divided into three categories based on catalytic activity and product type: type I, type II, and type III. Type I mainly includes PRMT1 / 2 / 3 / 4 / 6 / 8, which catalyze the substrate to form asymmetric dimethylarginine (ADMA); type II includes PRMT5 / 9, which catalyzes the substrate to form symmetric dimethylarginine (SDMA); type III only includes PRMT7, which is responsible for catalyzing the substrate to form monomethylarginine (MMA). PRMT5 uses S-adenosyl-L-methionine (SAM) as a methyl donor to transfer methyl groups to substrates such as DNA, RNA, and histones. The arginine residues of the substrate undergo symmetrical dimethylation to generate SDMA, thereby regulating multiple key cellular processes, including transcription, translation, and DNA repair, maintaining cell homeostasis, and also participating in regulating the growth and survival pathways of tumor cells and promoting tumor occurrence and development. Increased expression of PRMT5 has also been shown to be associated with poor prognosis in a variety of cancers, making it a highly potential epigenetic target.

[0003] Methylthioadenosine phosphorylase (MTAP) catalyzes methylthioadenosine (MTA) to generate methionine, which is essential for maintaining normal cell function. The deletion mutation of the MTAP gene causes MTA to accumulate in cells. MTA competes with the substrate SAM of PRMT5, which reduces the activity of PRMT5 and produces a large number of PRMT5-MTA complexes. The deletion of the MTAP gene increases the dependence of tumors on PRMT5. Inhibiting PRMT5 can have a "synthetic lethal" effect in tumors with MTAP deletion. PARP inhibitors based on the "synthetic lethal" theory have achieved great success in the field of precision treatment of tumors. The MTAP gene is adjacent to the most common tumor suppressor gene CDKN2A in human cancers, and is often co-deleted with CDKN2A. This co-deletion accounts for 10%-15% of all cancers, mainly occurring in non-small cell lung cancer (12%-20%), glioma (53%), pancreatic cancer (30%), and DLBCL (20%), with huge market prospects.

[0004] Currently, there are no PRMT5 inhibitors on the market. Early PRMT5 inhibitors are non-selective substrate SAM competitive inhibitors, which have serious blood toxicity and side effects in clinical practice and a small safety window. The first-generation PRMT5 inhibitors GSK-3326595, JNJ-64619178 and PF-06939999 have not made good clinical progress. The new generation of PRMT5 inhibitors targeting the PRMT5-MTA complex are only effective against MTAP-deficient and MTA-enriched tumors, have high selectivity for wild-type MTAP, reduce blood toxicity from a mechanistic perspective, and have been verified in preclinical studies, which is expected to significantly increase the safety window.

[0005] This patent involves a new PRMT5-MTA selective inhibitor, which is only active against MTAP-deficient cells and has weak inhibition on MTAP wild-type cells, thus avoiding the side effects such as blood toxicity caused by the clinical inhibition of MTAP wild-type by non-selective PRMT5 inhibitors. As a new type of PRMT5-MTA inhibitor, highly selective PRMT5-MTA inhibitors can be used to treat various tumors, cancers and other diseases. Summary of the invention

[0006] The object of the present invention is to provide a compound represented by the general formula (IA) or (IB), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0007]

[0008] M1 is selected from -N- or -CR 3e -;

[0009] M2 is selected from C, N or O; preferably C or O;

[0010] M3 is selected from C or N; preferably N;

[0011] Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl or 10-14 membered tricyclic group;

[0012] L1 is selected from a bond, -(CR aa R bb ) n4 -、-C(O)C(O)-、-C(O)C(O)NR cc -、-C(O)(CR aa R bb ) n4 -、-C(O)(CR aa R bb )n4 NR cc -、-C(O)NR cc (CR aa R bb ) n4 -、-C(O)C(O)NR cc -, -C(O)CRaa=, -C(O)CRaa=CR bb -、-(CR aa R bb ) n4 C(O)NR cc -、-C(O)-C 3-12 Cycloalkyl-, -C(O)-3-12 membered heterocyclic group-, -C(O)-C 6-12 Aryl-, -C(O)-5-12 membered heteroaryl-, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, substituted by one or more substituents; preferably -CR aa R bb -, -C(O)-, -C(O)C(O)-, -C(O)C(O)NR cc -、-C(O)(CR aa R bb )-、-C(O)(CR aa R bb )NR cc -、-C(O)NR cc (CR aa R bb )-、-C(O)C(O)NR cc -, -C(O)CRaa=, -C(O)CRaa=CR bb -、-(CR aa R bb )C(O)NRcc -、-C(O)-C 3-8 Cycloalkyl-, -C(O)-3-8 membered heterocyclic group-, -C(O)-C 6-10 Aryl-, -C(O)-5-10 membered heteroaryl, -C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0013] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0014] R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0015] Or any two R2 atoms are linked to their adjacent atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0016] R 3a , R 3b , R 3c , R 3d and R 3e are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR cR d or -P(O)R c R d , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0017] or R 3d and R 3e The atoms adjacent to it, R 3c and R 3d The atoms adjacent to it, R 3b and R 3c The adjacent atoms or R 3a and R 3b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0018] R 11a is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0019] R 11b is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0020] R a , R b , R c and R d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0021] R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0022] or R aa and R bb Linked with its neighboring atoms to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0023] x is selected from 0, 1, 2, 3, 4, 5 or 6;

[0024] y is selected from 0, 1, 2, 3, 4, 5 or 6; and

[0025] n4 is selected from 0, 1 or 2.

[0026] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that it is further represented by the general formula (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (II-I) or (II-J):

[0027]

[0028] Ring F is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; preferably C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8aryl and 5-8 membered heteroaryl; more preferably cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl, thienyl, tetrazolyl, triazolyl,

[0029] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group or C 6-12 Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0030] q is selected from 0, 1, 2, 3, 4, 5 or 6.

[0031] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that it is further represented by the general formula (VIII):

[0032]

[0033] Ring A is selected from 10-14 membered tricyclic groups;

[0034] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0035] R 2a , R 2b , R 2c and R 2d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)Ra 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0036] R 13 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group or C 6-12 Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0037] R a and Rb are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0038] x is selected from 0, 1, 2, 3, 4, 5 or 6; and

[0039] v is selected from 0, 1, 2, 3, 4, 5 or 6.

[0040] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that ring A is selected from a 5-8 membered saturated or unsaturated monocyclic heterocyclic group, a phenyl group or a 5-6 membered heteroaryl group; preferably a phenyl group, a pyridyl group, a pyrimidyl group, a pyridazinyl group or a pyrazinyl group.

[0041] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that ring A is selected from benzoC 5-8 Cycloalkyl, benzo 5-8 membered heterocyclic group, benzo 5-8 membered heteroaryl, 5-8 membered heteroaryl and C 5-8 Cycloalkyl, 5-8 membered heteroaryl and 5-8 membered heterocyclyl or 5-8 membered heteroaryl and 5-8 membered heteroaryl; preferably More preferred

[0043] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that ring A is selected from a 10-14 membered tricyclic ring system; preferably

[0044] M4 is C or N;

[0045] Ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0046] Ring C is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0047] Ring A is further preferably Further optimization

[0048] In a preferred embodiment of the present invention, the compound, its stereoisomer or its pharmaceutically acceptable salt is characterized in that R1 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -OR a 、-NR a R b or -C(O)NR a R b , the C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are substituted with one or more substituents; preferably selected from methyl, ethyl, difluoromethyl, trifluoromethyl, amino, -CH2NH2, -CH2NHCH3, -CH2NHCH2CH3, -CH2OH, -C(O)NH2;

[0049] R a and R b As defined in any embodiment.

[0050] Another object of the present invention is to provide a compound represented by general formula (III-A), (III-B), (III-C) or (III-D), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0051]

[0052] M1 is selected from -N- or -CR 3e -;

[0053] Ring D is selected from a saturated or unsaturated 3-8 membered heterocyclyl, a 5-12 membered spiroheterocyclyl, a 5-12 membered bridged heterocyclyl, a 5-12 membered fused heterocyclyl or a 5-8 membered heteroaryl;

[0054] R 3a , R 3b , R 3c , R 3d and R 3e are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c Rd or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0055] or R 3d and R 3e The atoms adjacent to it, R 3c and R 3d The atoms adjacent to it, R 3b and R 3c The adjacent atoms or R 3a and R 3b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0056] R 4a , R 4b and R 4c are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0057] or R 4a and R 4b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0058] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR eR f or -P(O)R e R f , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0059] R c , R d , R e and R f are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0060] n1 is selected from 0, 1 or 2; and

[0061] z is selected from 0, 1, 2, 3, 4, 5 or 6.

[0062] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that ring D is selected from a saturated or unsaturated 3-6-membered heterocyclic group, a 5-10-membered spiro heterocyclic group, a 5-10-membered bridged heterocyclic group, a 5-10-membered fused heterocyclic group; preferably

[0063]

[0064] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that ring D is selected from a 5-membered heteroaryl or a 6-membered heteroaryl; preferably selected from pyrazolyl, imidazolyl, thiazolyl, thienyl, oxazolyl, oxadiazolyl, triazolyl or tetrazolyl.

[0065] Another object of the present invention is to provide a compound represented by general formula (IV), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0066]

[0067] M2 is selected from C, N or O; preferably C or N;

[0068] Ring E is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0069] R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a Rb 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0070] Or any two R2 atoms are linked to their adjacent atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0071] R 4a , R 4b and R 4c are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0072] or R 4a and R 4b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0073] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR g 、-NR g R h 、-C(O)R g 、-C(O)NR g R h or -P(O)R g R h , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR g 、-NR g Rh 、-C(O)R g 、-C(O)NR g R h or -P(O)R g R h , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0074] R a , R b , R e , R f , R g and R h are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0075] y is selected from 0, 1, 2, 3, 4, 5 or 6; and

[0076] p is selected from 0, 1, 2, 3, 4, 5 or 6.

[0077] In a preferred embodiment of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof, is characterized in that ring B is selected from naphthyl, benzo 3-8 membered heterocyclyl, benzo 5-6 membered heteroaryl, 5-6 membered heteroaryl and 3-8 membered heterocyclyl, 5-6 membered heteroaryl and phenyl or 5-6 membered heteroaryl and 5-6 membered heteroaryl; ring B is preferably

[0078] Another object of the present invention is to provide a compound represented by general formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0079]

[0080] Ring G is selected from C 3-14 Cycloalkyl, 3-14 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 3-8 Cycloalkyl, C 6-14 Condensed cycloalkyl, 3-8 membered heterocyclic group, 6-14 membered condensed heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; more preferably Where · is a spiro atom;

[0081] R 4a , R 4b and R 4c are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -ORe 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0082] or R 4a and R 4b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0083] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR i 、-NR i R j 、-C(O)R i 、-C(O)NR i R j or -P(O)R i R j , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR i 、-NR i R j 、-C(O)R i 、-C(O)NR i R j or -P(O)R i R j , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0084] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR i 、-NR i R j 、-C(O)R i 、-C(O)NR i R j or -P(O)R i R j , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR i 、-NR i R j 、-C(O)R i 、-C(O)NR i R j or -P(O)R i R j , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0085] R e , R f , R i and Rj are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0086] n2 is selected from 0, 1 or 2;

[0087] n3 is selected from 0, 1 or 2;

[0088] r is selected from 0, 1, 2, 3, 4, 5 or 6; and

[0089] s is selected from 0, 1, 2, 3, 4, 5 or 6.

[0090] Another object of the present invention is to provide a compound represented by general formula (VI), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0091]

[0092] M1 is selected from -N- or -CR 3e -;

[0093] M2 is selected from C, N or O; preferably C or N;

[0094] R 3a , R 3b , R 3c , R 3d and R 3eare each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0095] or R 3d and R 3e The atoms adjacent to it, R 3c and R 3d The atoms adjacent to it, R 3b and R 3c The adjacent atoms or R 3a and R 3b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0096] R 4a , R 4b and R 4c are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NRe R f or -P(O)R e R f , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0097] or R 4a and The N atoms of the cyclopentane group are linked to form a saturated or unsaturated 8-14-membered heterocyclic group, which may be further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably forming a saturated or unsaturated 9-10 membered heterocyclic group, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0098] R 10 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0099] R c , R d , R e and R f are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0100] t is selected from 0, 1, 2, 3, 4, 5 or 6.

[0101] Another object of the present invention is to provide a compound represented by general formula (VII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0102]

[0103] Ring H is selected from C 3-14 Cycloalkyl, 3-14 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably 5-8 membered heterocyclic group and C 5-8 Cycloalkyl, 5-8 membered heterocyclyl and 5-8 membered heterocyclyl, 5-8 membered heterocyclyl and phenyl, or 5-8 membered heterocyclyl and 5-8 membered heteroaryl;

[0104] R 4a , R 4b and R 4c are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR e 、-NR e R f 、-C(O)R e 、-C(O)NR e R f or -P(O)R e R f , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0105] or R 4a and R 4b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0106] R N is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0107] R 12 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0108] R e and R f are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0109] u is selected from 0, 1, 2, 3, 4, 5 or 6.

[0110] Another object of the present invention is to provide a compound represented by the general formula (XI), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0111]

[0112] X1, X2 and X3 are each independently selected from N, NR m , O, CR m or CR m R n ;

[0113] Ring I is selected from C 3-14 Cycloalkyl, 3-14 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 6-12Aryl or 5-12 membered heteroaryl; more preferably phenyl, pyridyl, naphthyl, benzo C 5-8 Cycloalkyl, benzo 5-8 membered heterocyclic group or benzo 5-8 membered heteroaryl group;

[0114] R 2a , R 2b , R 2c and R 2d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0115] R 14 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group or C 6-12 Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0116] R 15 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR p 、-NR p R q 、-C(O)R p 、-C(O)NR p R q or -P(O)R p R q , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR p 、-NR p R q 、-C(O)R p 、-C(O)NR p R q or -P(O)R p R q , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0117] R a , R b , R m , R n , R p and R q are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;

[0118] p is selected from 0, 1, 2, 3, 4, 5 or 6; and

[0119] q is selected from 0, 1, 2, 3, 4, 5 or 6.

[0120] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of a compound shown in any one of the embodiments, a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0121] The present invention further relates to the use of the compound shown in any embodiment, its stereoisomer or pharmaceutically acceptable salt, or the pharmaceutical composition in the preparation of PRMT5 inhibitor drugs.

[0122] The present invention further relates to the use of the compound shown in any embodiment, its stereoisomer or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a drug for treating cancer, wherein the cancer is selected from MTAP-related cancers.

[0123] The present invention further relates to a method for preparing a method for treating cancer using a compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof as shown in any embodiment, wherein the cancer is selected from MTAP-related cancers.

[0124] In some embodiments, the cancer is selected from lung cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, head and neck cancer, glioma, glioblastoma, esophageal cancer, pancreatic cancer, mesothelioma, melanoma, astrocytoma, undifferentiated pleomorphic sarcoma, diffuse large B-cell lymphoma, leukemia, gastric adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, brain cancer, gastric cancer, kidney cancer, endometrial cancer, ovarian tumor, prostate cancer, lymphoma, non-Hodgkin lymphoma, urinary tract cancer, soft tissue cancer, pleural cancer, colon cancer, colorectal cancer or bile duct cancer; the lung cancer is selected from non-small cell lung cancer, squamous cell lung carcinoma or adenocarcinoma of the lung; the esophageal cancer is selected from esophageal squamous cell carcinoma or esophageal adenocarcinoma.

[0125] The present invention also relates to a method for preventing and / or treating cancer, which comprises administering to a patient a therapeutically effective dose of a compound shown in any embodiment, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0126] The present invention also relates to a method of treating cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.

[0127] In certain embodiments of the present invention, the weight percentage of the compound, its stereoisomer or pharmaceutically acceptable salt thereof in the pharmaceutical composition, calculated as free base, is 0.1% to 95%, preferably 90%, 85%, 80%, 75%, 70%, 60%, 50%.

[0128] In certain embodiments of the present invention, the pharmaceutical composition is selected from tablets, capsules, liquid preparations or injections, preferably, further comprising a filler, optionally a disintegrant, or further comprising one or more of a glidant or a lubricant.

[0129] In certain embodiments of the present invention, the pharmaceutical composition is an immediate-release formulation or a sustained-release formulation.

[0130] In certain embodiments of the present invention, the pharmaceutical composition, calculated as a free base, has a unit dose of 1-1000 mg, preferably 1-500 mg, or preferably 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg, 300 mg, 400 mg or 500 mg.

[0131] In certain embodiments of the invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof, may be administered by any convenient method, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, and the pharmaceutical composition adjusted accordingly.

[0132] In certain embodiments of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof can be formulated into liquid or solid preparations, such as syrups, suspensions, emulsions, tablets, capsules, powders, granules, or lozenges.

[0133] In some embodiments, the method relates to the treatment of conditions such as lung cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, head and neck cancer, glioma, glioblastoma, esophageal cancer, pancreatic cancer, mesothelioma, melanoma, astrocytoma, undifferentiated pleomorphic sarcoma, diffuse large B-cell lymphoma, leukemia, gastric adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, brain cancer, gastric cancer, kidney cancer, endometrial cancer, ovarian tumor, prostate cancer, lymphoma, non-Hodgkin lymphoma, urinary tract cancer, soft tissue cancer, pleural cancer, colon cancer, colorectal cancer, or bile duct cancer.

[0134] In some embodiments, the lung cancer is selected from non-small cell lung cancer, lung squamous cell carcinoma, or lung adenocarcinoma; and the esophageal cancer is selected from esophageal squamous cell carcinoma or esophageal adenocarcinoma.

[0135] Detailed description of the invention

[0136] Unless otherwise stated, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art. Specifically, the terms used in the specification and claims have the following meanings.

[0137] The term "alkyl" refers to a straight or branched saturated aliphatic hydrocarbon group, which may be optionally substituted with one or more substituents. In a specific embodiment, an alkyl group refers to a saturated aliphatic hydrocarbon group having 1 to 20 (C 1-20 ), 1 to 15 (C 1-15 ), 1 to 12 (C 1-12 ), 1 to 10 (C 1-10 ), 1 to 8 (C 1-8 ), 1 to 6 (C 1-6 ) or 1 to 3 (C 1-3 ) carbon atoms, or a straight-chain saturated hydrocarbon group having 3 to 20 (C 3-20 ), 3 to 15 (C 3-15 ), 3 to 12 (C 3-12 ), 3 to 10 (C 3-10 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 ) carbon atoms. The straight chain C 1-6 Alkyl and branched C 3-6 Alkyl groups are also called "lower alkyl". 1-6 Alkyl refers to a linear saturated monovalent hydrocarbon group having 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon group having 3 to 6 carbon atoms. 1-6The alkyl group contains 1 to 6 (e.g., 1, 2, 3, 4, 5, 6) carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-ethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl and various branched chain isomers thereof, and the like. In one embodiment, the alkyl group is an optionally substituted alkyl group described elsewhere herein.

[0138] The term "alkylene" refers to a further substitution of a hydrogen atom of an alkyl group, wherein "alkyl" is as defined above. Non-limiting examples of "alkylene" include: methylene (-CH2-), ethylene (-(CH2)2-), propylene (-(CH2)3-) or butylene (-(CH2)4-). In one embodiment, the alkylene group is an optionally substituted alkyl group described elsewhere herein.

[0139] The term "alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group containing at least one carbon-carbon double bond and the carbon-carbon double bond can be located at any position within the alkenyl group, and the alkenyl group can be optionally substituted with one or more substituents. In a specific embodiment, the alkenyl group is a group having 2 to 20 (C 2-20 ), 2 to 15 (C 2-15 ), 2 to 12 (C 2-12 ), 2 to 10 (C 2-10 ), 2 to 8 (C 2-8 ), 2 to 6 (C 2-6 ) or 2 to 4 (C 2-4 ) carbon atoms, or a straight-chain unsaturated hydrocarbon group having 3 to 20 (C 3-20 ), 3 to 15 (C3-15 ), 3 to 12 (C 3-12 ), 3 to 10 (C 3-10 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 ) carbon atoms. Unless otherwise specified, the term "alkenyl" as used herein includes both straight-chain and branched alkenyl groups. For example, C 2-6 Alkenyl refers to a straight chain unsaturated hydrocarbon group having 2 to 6 carbon atoms or a branched unsaturated hydrocarbon group having 3 to 6 carbon atoms. 2-6 The alkenyl group contains 2 to 6 (e.g., 2, 3, 4, 5, 6) carbon atoms. Non-limiting examples of alkenyl groups include: One of ordinary skill in the art will appreciate that the term "alkenyl" may also include groups having "cis" and "trans" configurations, or alternatively, groups having "E" and "Z" configurations. In one embodiment, the alkenyl is an optionally substituted alkenyl described elsewhere herein.

[0140] The term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and the carbon-carbon triple bond can be located at any position within the alkynyl group, and the alkynyl group can be optionally substituted with one or more substituents. In a specific embodiment, the alkynyl group is a 2 to 20 (C 2-20 ), 2 to 15 (C 2-15 ), 2 to 12 (C 2-12 ), 2 to 10 (C 2-10 ), 2 to 8 (C 2-8 ), 2 to 6 (C 2-6 ) or 2 to 4 (C 2-4 ) carbon atoms, or a straight-chain unsaturated hydrocarbon group having 3 to 20 (C 3-20 ), 3 to 15 (C 3-15 ), 3 to 12 (C 3-12 ), 3 to 10 (C 3-10 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 ) carbon atoms. Unless otherwise indicated, the term "alkynyl" as used herein includes both straight-chain and branched alkynyl groups. For example, C 2-6 Alkynyl refers to a straight chain unsaturated hydrocarbon group having 2 to 6 carbon atoms or a branched unsaturated hydrocarbon group having 3 to 6 carbon atoms. 2-6 Alkynyl groups contain 2 to 6 (e.g., 2, 3, 4, 5, 6) carbon atoms. Non-limiting examples of alkynyl groups include: In one embodiment, the alkynyl group is an optionally substituted alkynyl group described elsewhere herein.

[0141] The term "cycloalkyl" refers to a saturated or partially unsaturated aliphatic hydrocarbon monocyclic, polycyclic (two or more) cyclic group, which may be optionally substituted with one or more substituents. In a specific embodiment, the cycloalkyl ring contains 3 to 20 (C 3-20 ), 3 to 12 (C 3-12 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 ) carbon atoms; in one embodiment, the cycloalkyl ring contains 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 ) carbon atoms; it may contain one or more double bonds, but does not have a completely conjugated π electron system. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl or cyclooctyl, etc.; polycyclic cycloalkyls include spirocycloalkyls, fused cycloalkyls and bridged cycloalkyls in one embodiment. In one embodiment, the cycloalkyl is an optionally substituted cycloalkyl described elsewhere herein or a cycloalkyl optionally fused to a heterocyclyl, aryl or heteroaryl, non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc.

[0142] The term "spirocycloalkyl" refers to an aliphatic polycyclic group in which the single rings share a carbon atom (called a spiro atom), which may contain one or more double bonds, but none of the rings has a completely conjugated π electron system. In a specific embodiment, the spirocycloalkyl contains 5 to 20 (C 5-20 ), 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 ) (e.g., 7, 8, 9, 10) carbon atoms. According to the number of shared spiro atoms between rings, spirocycloalkyl is divided into single spirocycloalkyl, double spirocycloalkyl or multi-spirocycloalkyl, and in one embodiment is single spirocycloalkyl and double spirocycloalkyl. In one embodiment, it is 4 yuan / 4 yuan, 3 yuan / 5 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spirocycloalkyl. In one embodiment, the spirocycloalkyl is an optionally substituted spirocycloalkyl described elsewhere herein. Non-limiting examples of spirocycloalkyl include:

[0143]

[0144] The term "fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron system. In a specific embodiment, the fused cycloalkyl contains 5 to 20 (C 5-20), 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 ) (e.g., 7, 8, 9, 10) carbon atoms. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, in one embodiment, bicyclic or tricyclic, and further in one embodiment, 3-membered / 5-membered, 4-membered / 5-membered, 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. In one embodiment, the condensed cycloalkyl is an optionally substituted condensed cycloalkyl described elsewhere herein or a condensed cycloalkyl optionally fused to a heterocyclic group, an aryl group or a heteroaryl group. Non-limiting examples of condensed cycloalkyls include:

[0145]

[0146] The term "bridged cycloalkyl" refers to a full-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated π-electron system. In a specific embodiment, the bridged cycloalkyl contains 5 to 20 (C 5-20 ), 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 ) (e.g., 7, 8, 9, 10) carbon atoms. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic or tricyclic. In one embodiment, the bridged cycloalkyl is an optionally substituted bridged cycloalkyl described elsewhere herein. Non-limiting examples of bridged cycloalkyl include:

[0147]

[0148] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus or sulfur, wherein the nitrogen, phosphorus or sulfur atom may be optionally oxidized, the nitrogen atom may be optionally quaternized, the ring carbon atom may be optionally substituted by oxygen, but does not include the ring part of -OO-, -OS-, and the remaining ring atoms are carbon, which may contain one or more double bonds, but does not have a completely conjugated π electron system. In a specific embodiment, the heterocyclyl contains 3 to 20, 3 to 12, 3 to 8 or 3 to 6 ring atoms, of which 1 to 4 are heteroatoms; in one embodiment, the heterocyclyl contains 3 to 6, 4 to 6, 3 to 8, 3 to 10, 6 to 10 or 7 to 11 ring atoms; in one embodiment, the heterocyclyl contains 3 to 8 (e.g., 3, 4, 5, 6, 7, 8) ring atoms. The limiting examples of monocyclic heterocyclic radical include tetrahydropyrrolyl, azetidinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl and pyranyl etc..Polycyclic heterocyclic radical includes spiro heterocyclic radical, condensed heterocyclic radical and bridge heterocyclic radical.In one embodiment, the heterocyclic radical is the optionally substituted described elsewhere herein, or the heterocyclic radical further and ring-connected with other cycloalkyl, heterocyclic radical, aryl and heteroaryl by any two or more atoms on the ring.

[0149] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between the rings, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus or sulfur, and the remaining ring atoms are carbon, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. In a specific embodiment, the spiroheterocyclyl contains 5 to 20 or 6 to 14 ring atoms; in one embodiment, it contains 7 to 11 (e.g., 7, 8, 9, 10, 11) ring atoms; according to the number of spiro atoms shared between the rings, the spiroheterocyclyl is divided into a monospiroheterocyclyl, a bispiroheterocyclyl or a polyspiroheterocyclyl; preferably a monospiroheterocyclyl and a bispiroheterocyclyl; in one embodiment, the spiroheterocyclyl is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiroheterocyclyl; in one embodiment, the spiroheterocyclyl is an optionally substituted spiroheterocyclyl described elsewhere herein; non-limiting examples of spiroheterocyclyls include:

[0150]

[0151] The term "fused heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus or sulfur, and the remaining ring atoms are carbon. In a specific embodiment, the fused heterocyclic group is a heterocyclic group containing 5 to 20 or 6 to 14 ring atoms, and in one embodiment contains 7 to 10 (e.g., 7, 8, 9, 10) ring atoms; according to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group; preferably a bicyclic or tricyclic group; in one embodiment, it is a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group; in one embodiment, the fused heterocyclic group is a fused heterocyclic group described elsewhere herein that is optionally substituted or fused with a cycloalkyl, heterocyclic, aryl or heteroaryl group; non-limiting examples of fused heterocyclic groups include:

[0152]

[0153] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π electron system, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus or sulfur, and the remaining ring atoms are carbon. In a specific embodiment, the bridged heterocyclic group contains 5 to 20 or 6 to 14 ring atoms; in one embodiment, it contains 7 to 10 (e.g., 7, 8, 9, 10) ring atoms; according to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic group; preferably a bicyclic, tricyclic or tetracyclic group; in one embodiment, it is a bicyclic or tricyclic group; in one embodiment, the bridged heterocyclic group is an optionally substituted bridged heterocyclic group described elsewhere herein; non-limiting examples of bridged heterocyclic groups include:

[0154]

[0155] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group containing at least one conjugated π electron system, which may be optionally substituted by one or more substituents. In specific embodiments, the aryl group contains 6 to 20, 6 to 14, or 6 to 10 ring atoms; in one embodiment, the aryl group may further refer to a bicyclic, tricyclic, or tetracyclic ring system, wherein at least one ring is an aromatic ring, and the other rings may be saturated, partially unsaturated carbon rings, or rings containing one or more heteroatoms independently selected from O, S, and N; in one embodiment, the aryl group is selected from a benzo 5-10 membered heteroaryl, a benzo 3-10 membered cycloalkyl, or a benzo 3-10 membered heterocyclyl. In one embodiment, the aryl group is selected from a benzo 5-6 membered heteroaryl, a benzo 3-6 membered cycloalkyl, or a benzo 3-6 membered heterocyclyl, wherein the heterocyclyl group is a heterocyclyl group containing 1-3 nitrogen atoms, oxygen atoms, or sulfur atoms. Non-limiting examples include phenyl, naphthyl, fluorenyl, azulenyl, anthracenyl, phenanthrenyl, pyrenyl, biphenyl, terphenyl, dihydronaphthyl, indenyl, tetrahydronaphthyl (tetralinyl),

[0156] The term "arylene group" refers to a divalent aromatic group formed by further replacing one hydrogen atom of an aryl group, wherein the arylene group is optionally substituted or unsubstituted, and the aryl group is as defined above.

[0157] The term "heteroaryl" refers to an optionally substituted monocyclic, polycyclic group or ring system containing at least one aromatic ring, wherein the aromatic ring has one or more heteroatoms independently selected from O, S and N. In specific embodiments, the heteroaryl group contains 5 to 20, 5 to 15 or 5 to 10 ring atoms, of which 1 to 4 are heteroatoms; in one embodiment, the heteroaryl group contains 5 or 6 ring atoms; in specific embodiments, the heteroaryl group may further refer to a bicyclic, tricyclic or tetracyclic ring, wherein at least one ring is an aromatic ring having one or more heteroatoms independently selected from O, S and N, and the other rings may be saturated, partially unsaturated carbocyclic rings or rings containing one or more heteroatoms independently selected from O, S and N. In one embodiment, the heteroaryl group is selected from heteroaryl and 6-10 membered aryl, heteroaryl and 3-10 membered cycloalkyl or heteroaryl and 3-10 membered heterocyclyl; further in one embodiment, the heteroaryl group is selected from 5- or 6-membered heteroaryl and 6-10 membered aryl, 5- or 6-membered heteroaryl and 3-6 membered cycloalkyl, 5- or 6-membered heteroaryl and 3-6 membered heterocyclyl, wherein the heterocyclyl group is a heterocyclyl group containing 1-3 nitrogen atoms, oxygen atoms or sulfur atoms. Non-limiting examples include furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, triazolyl, benzofuranyl, benzimidazolyl, benzisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiophenyl, benzothiophenyl, benzotriazolyl, imidazopyridinyl, imidazothiazolyl , indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothiophenyl, isoindolyl, isoquinolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridinyl, pyrrolopyridinyl, quinolyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidinyl, thienopyridinyl, acridinyl, benzindolyl, carbazolyl, bibenzofuranyl, phenanthrolinyl, phenanthridinyl, phenpyrazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl,

[0158] The term "heteroarylene" refers to a divalent heteroaryl group formed by further replacing one hydrogen atom of a cycloalkyl group, wherein the heteroarylene group is optionally substituted or unsubstituted, and the heteroaryl group is as defined above.

[0159] The term "tricyclic group" or "tricyclic ring system" refers to a group consisting of three rings, wherein two rings each share a pair of adjacent atoms with the third ring or three rings share four adjacent atoms, and the rings are selected from cycloalkyl, heterocyclyl, aryl or heteroaryl, and cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted or unsubstituted, and cycloalkyl, heterocyclyl, aryl and heteroaryl are defined as above. In specific embodiments, "tricyclic group" or "tricyclic ring system" contains 6 to 20 ring atoms, 8 to 20 ring atoms or 10 to 20 ring atoms; in one embodiment, it contains 10 to 14 (e.g., 10, 11, 12, 13, 14 ring atoms) ring atoms; non-limiting examples thereof include:

[0160]

[0161] The term "heteroalkyl" refers to a stable straight or branched chain, or cyclic hydrocarbon group, or a combination thereof, consisting of the indicated number of carbon atoms and one or more (in one embodiment, one to three) heteroatoms selected from O, N, Si, and S, and wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. In one embodiment, the heteroatoms O, N, and S may be placed at any interior position of the heteroalkyl group. In one embodiment, the heteroatom Si may be placed at any position (e.g., interior or terminal position) of the heteroalkyl group, including the position where the alkyl group is attached to the remainder of the molecule. Non-limiting examples thereof include: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Up to two heteroatoms may be consecutive, for example, -CH2-NH-O-CH3 and -CH2-O-Si(CH3)3. In a particular embodiment, the heteroalkyl group is an optionally substituted heteroalkyl group described elsewhere herein.

[0162] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl or cycloalkyl are as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or cyclohexyloxy. In one embodiment, the alkoxy is an optionally substituted alkoxy described elsewhere herein.

[0163] The term "alkylacyl" refers to a -C(O)-alkyl group, wherein alkyl is as previously defined.

[0164] The term "haloalkyl" refers to an alkyl group substituted by one or more halogens, wherein the definition of alkyl is the same as above. Non-limiting examples of the haloalkyl group include: trifluoromethyl, -CH2CF3,

[0165] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogen groups, wherein alkoxy is as defined above.

[0166] The term "hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.

[0167] The term "alkylthio" refers to -S-(alkyl) and -S-(unsubstituted cycloalkyl), wherein alkyl or cycloalkyl are as defined above. Non-limiting examples of alkylthio include: methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio or cyclohexylthio. In one embodiment, the alkylthio is an optionally substituted alkylthio described elsewhere herein.

[0168] The term "haloalkylthio" refers to an alkylthio group substituted with one or more halogens, wherein alkylthio is as defined above.

[0169] The term "alkenylcarbonyl" refers to -C(O)-(alkenyl), wherein alkenyl is as defined above. Non-limiting examples of alkenylcarbonyl include: vinylcarbonyl, propenylcarbonyl, or butenylcarbonyl. In one embodiment, the alkenylcarbonyl is an optionally substituted alkenylcarbonyl described elsewhere herein.

[0170] The term "aminocarbonyl" refers to NH2-C(O)-.

[0171] The term "alkylaminocarbonyl" refers to an aminocarbonyl (NH2-C(O)-) group in which one or both of the two hydrogen atoms are replaced by alkyl groups, wherein the alkyl group has the same definition as above.

[0172] The term "alkylamino" refers to an amino group in which one or both of the two hydrogen atoms are replaced by an alkyl group, wherein the alkyl group has the same definition as above.

[0173] The term "carbonyl" refers to a -C(O)-, -(CO)-, or -C(=O)- group. All notations are used interchangeably in the specification.

[0174] “-C(O)CR aa =" means that when it acts as a connecting bond, one end is directly connected to a single bond and the other end is directly connected to a double bond.

[0175] The term "hydroxy" refers to an -OH group.

[0176] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0177] The term "hydrogen" includes protons (1 H), deuterium ( 2 H), tritium ( 3 H) and / or mixtures thereof. In a particular embodiment, one or more positions occupied by hydrogen in the compound may be enriched with deuterium and / or tritium. Such isotopically enriched analogs may be prepared from suitable isotopically labeled starting materials obtained from commercial sources or prepared by known literature procedures.

[0178] The alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylene, heteroaryl, heteroarylene, heteroalkyl, alkoxy, alkylthio, hydroxyalkyl, alkenylcarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylamino, and alkylacyl may be substituted or unsubstituted. In one embodiment, the substituent is selected from one or more of the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, alkylacyl, halogen, sulfhydryl, hydroxyl, nitro, cyano, azido, oxime, phosphate, oxo, thio, carboxyl, carboxylate, cycloalkyl, heterocyclyl, aryl, heteroaryl, heterocycloalkyloxy, cycloalkylthio, or heterocycloalkylthio.

[0179] Different expressions such as “X is selected from A, B, or C”, “X is selected from A, B and C”, “X is A, B or C”, “X is A, B and C” all express the same meaning, that is, X can be any one or more of A, B, C.

[0180] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.

[0181] In various parts of the present invention, linking substituents are described. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood as a linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl", it should be understood that the "alkyl" or "aryl" represents an alkylene group or an arylene group, respectively, that is linked.

[0182] "Substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable in one embodiment. In one embodiment. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced. The term "optionally substituted" means that it may be substituted or not substituted, and unless otherwise specified, the type and number of the substituent may be arbitrary on the basis of chemical realization. It goes without saying that the substituent is only in their possible chemical position, and those skilled in the art can determine (by experiment or theory) possible or impossible substitution without paying too much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (such as olefinic) bond.

[0183] In this specification and the claims, the indefinite articles "a" and "an" and the definite article "the" include plural as well as singular, unless stated to the contrary.

[0184] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0185] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity.

[0186] "Stereoisomers" encompass all enantiomerically / diastereomerically / stereomerically pure and enantiomerically / diastereomerically / stereomerically enriched forms of the compounds of the invention.

[0187] "Stereomerically pure" refers to a composition comprising one stereoisomer of a compound and being substantially free of another stereoisomer of the compound. For example, a stereomerically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereoisomerically pure compound contains greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of another stereoisomer of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of another stereoisomer of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of another stereoisomer of the compound, greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of another stereoisomer of the compound, or greater than about 99% by weight of one stereoisomer of the compound and less than about 1% by weight of another stereoisomer of the compound.

[0188] "Stereoisomerically enriched" refers to a composition comprising greater than about 55% by weight, greater than about 60% by weight, greater than about 70% by weight, or greater than about 80% by weight of one stereoisomer of a compound.

[0189] "Enantiomerically pure" refers to a stereomerically pure composition of a compound having one chiral center. Similarly, the term "enantiomerically enriched" refers to a stereomerically enriched composition of a compound having one chiral center.

[0190] "Optically active" and "enantiomeric activity" refer to a combination of molecules having an enantiomeric or diastereomeric excess of not less than about 50%, not less than about 70%, not less than about 80%, not less than about 90%, not less than about 91%, not less than about 92%, not less than about 93%, not less than about 94%, not less than about 95%, not less than about 96%, not less than about 97%, not less than about 98%, not less than about 99%, not less than about 99.5%, or not less than about 99.8%. In certain embodiments, the compound comprises about 95% or more of the desired enantiomer or diastereomer and about 5% or less of the less preferred enantiomer or diastereomer, based on the total weight of the racemate.

[0191] When describing an optically active compound, the prefixes R and S are used to denote the absolute configuration of the molecule with respect to its chiral center. (+) and (-) are used to denote the optical rotation of the compound, i.e., the direction of the plane of polarized light rotated by the optically active compound. The prefix (-) indicates that the compound is levorotatory, i.e., the compound rotates the plane of polarized light to the left or counterclockwise. The prefix (+) indicates that the compound is dextrorotatory, i.e., the compound rotates the plane of polarized light to the right or clockwise. However, the signs (+) and (-) of the optical rotation have nothing to do with the absolute configuration, R and S, of the molecule. DETAILED DESCRIPTION

[0192] The present invention is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present invention.

[0193] Example

[0194] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the solvent, and tetramethylsilane (TMS) as the internal standard.

[0195] MS was measured using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQadvantage MAX).

[0196] HPLC was performed using an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C 18 150×4.6 mm chromatographic column) and Waters 2695-2996 high pressure liquid chromatograph (Gimini C 18 150×4.6mm chromatographic column).

[0197] Average kinase inhibition rate and IC 50 The values ​​were determined using NovoStar microplate reader (BMG, Germany).

[0198] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) adopts a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.

[0199] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0200] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, Darui Chemicals and other companies.

[0201] Unless otherwise specified in the examples, the reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.

[0202] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.

[0203] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.

[0204] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or a HC2-SS hydrogenator.

[0205] The hydrogenation reaction is usually carried out by evacuating the vacuum, filling with hydrogen, and repeating the operation three times.

[0206] The microwave reaction was carried out using a CEM Discover-S 908860 microwave reactor.

[0207] Unless otherwise specified in the examples, the solution refers to an aqueous solution.

[0208] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.

[0209] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), and the developing solvent systems used in the reaction are: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, D: acetone, and the volume ratio of the solvent is adjusted according to the polarity of the compound.

[0210] The eluent system of column chromatography and the developing solvent system of thin layer chromatography used for purifying compounds include: A: n-hexane and ethyl acetate system, B: n-hexane and tetrahydrofuran system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.

[0211] Example 1

[0212] N-(5-amino-1,6-naphthyridin-8-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-carbonylacetamide

[0213]

[0214] first step

[0215] 8-Bromo-N-(4-methoxybenzyl)-1,6-naphthyridin-5-amine

[0216] 8-Bromo-1,6-naphthyridin-5-amine 1a (1 g, 4.48 mmol) and cesium carbonate (2.18 g, 6.72 mmol) were dispersed in 20 mL of dimethylformamide, 4-methoxybenzyl chloride (842 mg, 5.38 mmol) was added, and the reaction was stirred at 100°C for 5 hours. The reaction solution was poured into ethyl acetate (150 mL), washed with water (150 mL) and saturated sodium chloride solution (150 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system B to obtain the title product 8-bromo-N-(4-methoxybenzyl)-1,6-naphthyridin-5-amine 1b (1.14 g) in a yield of 74.2%.

[0217] MS m / z(ESI):344[M+1]

[0218] Step 2

[0219] 2-((5-((4-methoxybenzyl)amino)-1,6-naphthyridin-8-yl)amino)-2-oxoacetic acid

[0220] Disperse 8-bromo-N-(4-methoxybenzyl)-1,6-naphthyridin-5-amine 1b (1.14 g, 3.32 mmol), ethyl oxalamide (427 mg, 3.65 mmol), tris(dibenzylideneacetone)dipalladium (302 mg, 0.33 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (381 mg, 0.66 mmol) and cesium carbonate (1.62 g, 4.98 mmol) in 20 mL of dimethylformamide, and heat and stir the reaction at 130° C. under nitrogen protection for 16 hours. The reaction solution was poured into ethyl acetate (150 mL), and 50 ml of water was added. The pH of the reaction solution was adjusted to acidic with 2M hydrochloric acid, and the reaction solution was washed with water (150 mL) and saturated sodium chloride solution (150 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System C to give the title product 2-((5-((4-methoxybenzyl)amino)-1,6-naphthyridin-8-yl)amino)-2-carbonylacetic acid 1c (280 mg) in a yield of 24.0%.

[0221] MS m / z(ESI):352[M+1]

[0222] Step 3

[0223] 2-((2R,5S)-2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-N-(5-((4-methoxybenzyl)amino)-1,

[0224] 6-naphthyridin-8-yl)-2-carbonylacetamide

[0225] 2-((5-((4-methoxybenzyl)amino)-1,6-naphthyridin-8-yl)amino)-2-carbonylacetic acid 1c (280 mg, 0.80 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (456 mg, 1.2 mmol) and 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole (204 mg, 0.88 mmol, synthesized by the known method "Patent WO2022026892Al") were dispersed in 20 mL of dimethylformamide, triethylamine (242 mg, 2.4 mmol) was added, and the reaction was stirred at room temperature for 16 hours. The reaction solution was poured into ethyl acetate (50 mL), washed with water (50 mL) and saturated sodium chloride solution (50 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System B to give the title product 2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-N-(5-((4-methoxybenzyl)amino)-1,6-naphthyridin-8-yl)-2-carbonylacetamide 1d (113 mg) in a yield of 24.9%.

[0226] MS m / z(ESI):567[M+1]

[0227] Step 4

[0228] N-(5-amino-1,6-naphthyridin-8-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl

[0229] 2-Carboacetamide

[0230] 2-((2R,5S)-2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-N-(5-((4-methoxybenzyl)amino)-1,6-naphthyridin-8-yl)-2-carboacetamide 1d (113 mg, 0.20 mmol) was dissolved in 5 mL of trifluoroacetic acid and the reaction was stirred at 85°C for 16 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent System C to give the title product 2-((2R,5S)-2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-N-(5-((4-methoxybenzyl)amino)-1,6-naphthyridin-8-yl)-2-carboacetamide 1 (55 mg) in a yield of 61.5%.

[0231] MS m / z(ESI):447[M+1]

[0232] Examples 2 to 18 and 97 to 101 were obtained by referring to the method of Example 1.

[0233]

[0234]

[0235]

[0236] The following examples were obtained by referring to the method of Example 1.

[0237]

[0238]

[0239]

[0240]

[0241]

[0242] Example 2

[0243] N-(4-amino-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide

[0244]

[0245] first step

[0246] 2-(2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetic acid

[0247] 5-(5-Methylpiperidin-2-yl)benzo[d]thiazole 2a (2.32 g, 10 mmol, synthesized by the known method "Patent WO2022026892A1") was dissolved in 50 mL of tetrahydrofuran, sodium hydride (60 mg, 1.50 mmol, 60%) was added at 0°C, and the reaction was stirred at 0°C for 1 h. Then, ethyl oxalyl chloride (271 μL, 2.43 mmol) was added at 0°C, and the reaction was stirred at 20°C for 12 hours. The reaction solution was quenched by adding 3 mL of water, concentrated under reduced pressure, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title product, ethyl 2-((4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)amino)-2-oxoacetate 2b, as a crude product (2.70 g), which was directly used in the next step without separation and purification.

[0248] MS m / z(ESI):319[M+1]

[0249] Step 2

[0250] 2-(2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide

[0251] The crude product ethyl 2-((4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)amino)-2-oxoacetate 2b (2.70 g, 8.85 mmol) was dissolved in 50 mL of ammonia methanol solution and stirred at 20°C for 12 h. The reaction solution was concentrated under reduced pressure and the residue was purified by reverse phase column chromatography with eluent system C to give the title product 2-(2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2c (2.31 g) in a yield of 88.9%.

[0252] MS m / z(ESI):304[M+1]

[0253] Step 3

[0254] 2-((2R,5S)-2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide

[0255] 2-(2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2c (2.31 g, 7.60 mmol) was separated by chiral HPLC to give the title product 2-((2R,5S)-2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2d (1.13 g) with a recovery rate of 48.9%.

[0256] MS m / z(ESI):304[M+1]

[0257] Step 4

[0258] 2,4,5-Tribromo-3-cyanopyridine

[0259] 5-Bromo-2-hydroxy-4-methoxynicotinonitrile 2e (4.58 g, 20 mmol, synthesized by the known method "Journal of Heterocyclic Chemistry, 2020, 57 (1), 486-496") was dissolved in 50 mL of acetonitrile, and phosphorus oxybromide (4.07 mL, 40 mmol) was added, and the reaction was stirred at 80 ° C for 12 h. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title product 2,4,5-tribromo-3-cyanopyridine 2f (5.31 g) with a yield of 77.9%.

[0260] MS m / z(ESI):341[M+1]

[0261] Step 5

[0262] 2,4,5-Tribromonicotinaldehyde

[0263] 2,4,5-Tribromo-3-cyanopyridine 2f (5.31 g, 15.57 mmol) was dissolved in 80 mL of toluene, cooled to -40°C, and a 1 M toluene solution of DIBAL-H (10.13 mL) was added, and the reaction was stirred at -40°C for 1 h. Saturated ammonium chloride solution was added to the reaction solution to quench, and the reaction solution was naturally warmed to room temperature, concentrated under reduced pressure, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 2,4,5-tribromonicotinaldehyde 2g (3.37 g) with a yield of 63.0%.

[0264] MS m / z(ESI):344[M+1]

[0265] Step 6

[0266] 4,7-Dibromo-1H-pyrazolo[4,3-c]pyridine

[0267] 2g (3.37g, 9.81mmol) of 2,4,5-tribromonicotinaldehyde was dissolved in 50mL of ethanol, and 1.12mL of hydrazine hydrate (19.62mmol, 85%) was added, and the mixture was stirred under reflux for 6h. The reaction solution was cooled to room temperature, concentrated under reduced pressure, extracted with ethyl acetate (20mL×2), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 4,7-dibromo-1H-pyrazolo[4,3-c]pyridine 2h (1.12g), with a yield of 41.2%.

[0268] MS m / z(ESI):278[M+1]

[0269] Step 7

[0270] 4,7-Dibromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine

[0271] 4,7-dibromo-1H-pyrazolo[4,3-c]pyridine 2h (1.12 g, 4.04 mmol) was dissolved in 40 mL of chloroform, p-toluenesulfonic acid (69 mg, 0.40 mmol) and 3,4-dihydro-2H-pyran (1.84 mL, 20.20 mmol) were added, and the mixture was stirred under reflux for 24 h. The reaction solution was cooled to room temperature, quenched by adding 1 mL of saturated sodium bicarbonate solution, concentrated under reduced pressure, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 4,7-dibromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine 2i (1.33 g) with a yield of 90.9%.

[0272] MS m / z(ESI):362[M+1]

[0273] Step 8

[0274] 7-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine

[0275] 4,7-Dibromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine 2i (1.33 g, 3.67 mmol) was dissolved in 30 mL of dimethyl sulfoxide, and cuprous oxide (525 mg, 0.37 mmol) and 5 mL of methylamine aqueous solution were added, and the mixture was stirred at 100°C for 12 h. The reaction solution was cooled to room temperature, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 7-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine-4-amine 2j (808 mg) with a yield of 74.1%.

[0276] MS m / z(ESI):297[M+1]

[0277] Step 9

[0278] N-(4-amino-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo

[0279] [d] Thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide

[0280] 2-((2R,5S)-2-(Benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2d (303 mg, 1 mmol), 7-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine 2j (297 mg, 1 mmol), (1S,2S)-N,N-dimethylcyclohexane (213 mg, 1.50 mmol), copper powder (64 mg, 1 mmol), cesium carbonate (651 mg, 2 mmol) and cuprous iodide (190 mg, 1 mmol) were dispersed in 10 mL of 1,4-dioxane and stirred at 100°C for 15 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to give the title product, N-(4-amino-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2k (202 mg) in a yield of 38.8%.

[0281] MS m / z(ESI):520[M+1]

[0282] Step 10

[0283] N-(4-amino-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide

[0284] Disperse N-(4-amino-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2k (202 mg, 0.38 mmol) in 5 mL of methanol, add 5 mL of hydrochloric acid / 1,4-dioxane, and stir at 20°C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent System A to give the title product, N-(4-amino-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 2k (167 mg) in a 100% yield.

[0285] MS m / z(ESI):436[M+1]

[0286] Embodiment 19

[0287] (1-((6-amino-5-methylpyridin-3-yl)amino)cyclopropyl)((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)methanone

[0288]

[0289]

[0290] first step

[0291] 1-((6-amino-5-methylpyridin-3-yl)amino)cyclopropyl-1-carboxylic acid

[0292] 3-Methylpyridine-2,5-diamine 19a (500 mg, 4.06 mmol) and 1-chlorocyclopropyl-1-carboxylic acid 19b (480 mg, 4 mmol) were dispersed in 5 mL of acetonitrile, and triethylamine (505 mg, 5 mmol) was added, and the mixture was stirred at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system B to obtain the title product 1-((6-amino-5-methylpyridin-3-yl)amino)cyclopropyl-1-carboxylic acid 19c (624 mg) in a yield of 75.1%.

[0293] MS m / z(ESI):208[M+1]

[0294] Step 2

[0295] (S)-tert-Butyl (5-(Benzo[d]thiazol-5-yl)-2-methyl-5-oxopentyl)carbamate

[0296] 5-Bromobenzothiazole 19d (1 g, 4.69 mmol) was dispersed in 10 mL of tetrahydrofuran, and n-butyl lithium (2 mL, 5 mmol, 2.5 M / L tetrahydrofuran solution) was added dropwise at -70°C. The reaction was stirred at -70°C for 1 hour. (S)-tert-butyl 5-methyl-2-oxopiperidin-1-carboxylate 19e (1.06 g, 5 mmol) was added. The reaction was stirred at -70°C for 1 hour. Saturated aqueous ammonium chloride solution was added dropwise to the reaction solution to quench the reaction. The filtrate was filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to obtain the title product (S)-tert-butyl (5-(benzo[d]thiazol-5-yl)-2-methyl-5-oxopentyl)carbamate 19f (1.04 g) in a yield of 63.9%.

[0297] MS m / z(ESI):349[M+1]

[0298] Step 3

[0299] (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole

[0300] Tert-butyl (S)-(5-(Benzo[d]thiazol-5-yl)-2-methyl-5-oxopentyl)carbamate 19f (1.04 g, 3 mmol) was dispersed in 10 mL of trifluoroacetic acid and stirred at 25°C for 1 hour. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent system B to give the title product (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole 19g (250 mg) in a yield of 36.1%.

[0301] MS m / z(ESI):231[M+1]

[0302] Step 4

[0303] 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole

[0304] Disperse (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole 19g (250mg, 1.08mmol) in 5mL methanol and add sodium borohydride (76mg, 2mmol) at 0℃. Stir the reaction at 25℃ for 1 hour. Add 1mL saturated aqueous ammonium chloride solution to quench the reaction. Filter, concentrate the filtrate under reduced pressure, and purify the residue by silica gel column chromatography with eluent system B to obtain the title product 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole 19g (116mg), yield: 46.3%.

[0305] MS m / z(ESI):233[M+1]

[0306] Step 5: (1-((6-amino-5-methylpyridin-3-yl)amino)cyclopropyl)((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)methanone

[0307] 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole 19g (80 mg, 0.34 mmol) and 1-((6-amino-5-methylpyridin-3-yl)amino)cyclopropyl-1-carboxylic acid 19c (104 mg, 0.5 mmol) were dispersed in 4 mL of dichloromethane and 1 mL of pyridine, and phosphorus oxychloride (153 mg, 1 mmol) was added dropwise at 0°C. The reaction was stirred at 25°C for 1 hour. The reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give the title product (1-((6-amino-5-methylpyridin-3-yl)amino)cyclopropyl)((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)methanone 19 (42 mg) in a yield of 29.4%.

[0308] MS m / z(ESI):422[M+1]

[0309] Examples 20 to 51, 102 to 111, and 114 were obtained by referring to the method of Example 19.

[0310]

[0311]

[0312]

[0313]

[0314]

[0315] The following examples were obtained by referring to the method of Example 19.

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323] Embodiment 52

[0324] N-(6-amino-5-methylpyridin-3-yl)-2-(2-benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidin-1-yl

[0325] 2-Oxoacetamide

[0326]

[0327] first step

[0328] 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[c][1,2,5]thiadiazole

[0329] 5-Bromobenzo[c][1,2,5]thiadiazole 52a (5.0 g, 23.25 mmol) was added to a reaction flask, and 1,4-dioxane (15 mL), biboronic acid pinacol ester (8.856 g, 34.88 mmol), potassium acetate (4.564 g, 46.5 mmol) were added. The reaction system was replaced with nitrogen three times, and Pd(dppf)Cl2 (1.687 g, 2.345 mmol) was added under nitrogen protection. The reaction was stirred at 100°C for 16 hours; the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system C to obtain 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[c][1,2,5]thiadiazole 52b (5.0 mg) in a yield of 82.1%.

[0330] MS m / z(ESI):263.1[M+1]

[0331] Step 2

[0332] tert-Butyl 6-(Benzo[c][1,2,5]thiadiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)carboxylate

[0333] 3-Methyl-6-(trifluoromethylsulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 52c (2.0 g, 5.79 mmol, synthesized by the known method patent "WO2022026892A1") was added to the reaction bottle, and 1,4-dioxane (20 mL), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[c][1,2,5]thiadiazole 52b (2.28 g, 8.69 mmol), sodium carbonate ( The reaction system was purged with nitrogen three times, and Pd(dppf)Cl2 (420.2 mg, 0.579 mmol) was added under nitrogen protection. The reaction was stirred at 80°C for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system C to obtain tert-butyl 6-(benzo[c][1,2,5]thiadiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)carboxylate 52d (1.25 g). The yield was 65.0%.

[0334] MS m / z(ESI):332.4[M+1]

[0335] Step 3

[0336] tert-Butyl 2-(Benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidine-1-carboxylate

[0337] 6-(Benzo[c][1,2,5]thiadiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)carboxylic acid tert-butyl ester 52d (1.2 g, 3.62 mmol) was added to a reaction flask, and dichloromethane (20 mL) and trifluoroacetic acid (825.5 mg, 7.24 mmol) were added, and the mixture was stirred at 25°C for 1 hour; the reaction solution was concentrated under reduced pressure, methanol (20 mL) was added to the concentrated residue, and sodium borohydride (273.9 mg, 7.24 mmol) was added at 0°C. 1), the reaction was stirred at 25°C for 1 hour, and then di-tert-butyl dicarbonate (1.19 g, 5.43 mmol) and sodium carbonate (575.6 mg, 5.43 mmol) were added. The reaction was stirred at 25°C for 12 hours; the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system C to obtain tert-butyl 2-(benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidine-1-carboxylate 52e (847.0 mg), yield: 70.0%.

[0338] MS m / z(ESI):334.5[M+1]

[0339] Step 4

[0340] 5-(5-Methylpiperidin-2-yl)benzo[c][1,2,5]thiadiazole

[0341] tert-Butyl 2-(Benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidine-1-carboxylate 52e (800 mg, 2.4 mmol) was added to a reaction flask, and methanol (10 mL) and 2M dilute hydrochloric acid (2.4 mL, 4.8 mmol) were added, and the mixture was stirred at 25°C for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system C to give 5-(5-methylpiperidin-2-yl)benzo[c][1,2,5]thiadiazol 52f (350.0 mg) in a yield of 62.5%.

[0342] MS m / z(ESI):234.3[M+1]

[0343] Step 5

[0344] N-(6-amino-5-methylpyridin-3-yl)-2-(2-benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidin-1-yl

[0345] 2-Oxoacetamide

[0346] 2-((6-amino-5-methylpyridin-3-yl)amino)-2-oxoacetic acid 52g (376.42mg, 1.93mmol, synthesized by the known method patent "WO2022026892A1") was added to a reaction bottle, and N,N-dimethylformamide (5mL), N,N-diisopropylethylamine (500.2mg, 3.87mmol), HATU (981.1mg, 2.58mmol), 5-(5-methylpiperidin-2-yl)benzo[c][1,2,5]thiadiazole 52f (300mg, 1.29mmol) were added, and the reaction system was replaced with nitrogen three times and protected with nitrogen. The reaction was stirred at 25°C for 1 hour; ethyl acetate extraction (20mL) and saturated brine (20mL) were added, and the aqueous layer was The mixture was extracted with ethyl acetate (20 mL×2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System C to give N-(6-amino-5-methylpyridin-3-yl)-2-(2-benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 52 (321.90 mg), yield: 61.0%; the compound was separated by chiral SFC to give N-(6-amino-5-methylpyridin-3-yl)-2-(2R,5S)-2-benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 52-1 (60.00 mg), yield: 18.6%, dr value: 98%.

[0347] MS m / z(ESI):411.5[M+1]

[0348] Examples 53 to 61 were obtained by referring to the method of Example 52.

[0349]

[0350]

[0351]

[0352]

[0353]

[0354] Embodiment 62

[0355] (R)-N-(6-amino-5-methylpyridin-3-yl)-2-(2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]heptane-1-

[0356] 2-Carboacetamide

[0357]

[0358] first step

[0359] tert-Butyl 2-carbonyl-1-azaspiro[3.3]heptane-1-carboxylate

[0360] 1-Azaspiro[3.3]heptane-2-one 62a (10 g, 89.98 mmol) and di-tert-butyl dicarbonate (19.64 g, 89.99 mmol) were dissolved in 50 mL of dichloromethane, followed by the addition of triethylamine (9.1 g, 89.93 mmol) and 4-dimethylaminopyridine (1.1 mg, 9.0 mmol), and the mixture was stirred at 20° C. for 2 hours. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to obtain tert-butyl 2-carbonyl-1-azaspiro[3.3]heptane-1-carboxylate 62b (15 g) in a yield of 78.9%.

[0361] MS m / z(ESI):212[M+1]

[0362] Step 2

[0363] Tert-butyl 2-(((trifluoromethyl)sulfonyl)oxy)-1-azaspiro[3.3]hept-2-ene-1-carboxylate

[0364] Tert-butyl 2-carbonyl-1-azaspiro[3.3]heptane-1-carboxylate 62b (15 g, 71.00 mmol) was dissolved in 200 mL of tetrahydrofuran and then condensed to -78°C. Sodium bis(trimethylsilyl)amide (53 ml, 2M, 106.0 mmol) was added at -78°C. After stirring for 2 hours at -78°C, N-phenylbis(trifluoromethanesulfonyl)imide (37.87, 106.0 mmol) was added at -78°C. The reaction was continued at 20°C for 10 hours. Saturated ammonium chloride was added to quench the reaction. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent system A to give tert-butyl 2-(((trifluoromethyl)sulfonyl)oxy)-1-azaspiro[3.3]hept-2-ene-1-carboxylate 62c (12 g) in a yield of 49.2%.

[0365] MS m / z(ESI):344[M+1]

[0366] Step 3

[0367] Tert-butyl 2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]hept-2-ene-1-carboxylate

[0368] Tert-butyl 2-(((trifluoromethyl)sulfonyl)oxy)-1-azaspiro[3.3]hept-2-ene-1-carboxylate 62c (12 g, 34.95 mmol) and 5-benzothiazolylpinacol borate 62d (9 g, 34.46 mmol) were dissolved in 50 mL of dioxane and 10 mL of water, followed by the addition of 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride (2.5 g, 3.44 mmol) and sodium carbonate (7.5 g, 70.76 mmol), and the mixture was stirred at 100° C. for 2 hours. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to give tert-butyl 2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]hept-2-ene-1-carboxylate 62e (6 g) in a yield of 52.3%.

[0369] MS m / z(ESI):329[M+1]

[0370] Step 4

[0371] tert-Butyl 2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]heptane-1-carboxylate

[0372] Tert-butyl 2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]hept-2-ene-1-carboxylate 62e (6 g, 18.27 mmol) was dissolved in 50 mL of methanol, and Pd / C (2 g) was added to react under a hydrogen atmosphere at 30°C with stirring for 12 hours. After cooling, the reaction solution was filtered and concentrated under reduced pressure to obtain tert-butyl 2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]heptane-1-carboxylate 62f (4 g), 66.2%.

[0373] MS m / z(ESI):331[M+1]

[0374] Step 5

[0375] 5-(1-Azaspiro[3.3]heptane-2-yl)benzo[d]thiazole

[0376] Tert-butyl 2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]heptane-1-carboxylate 62f (4 g, 12.11 mmol) was dissolved in 50 mL of methanolic hydrochloric acid (4 M) and stirred at 30°C for 12 hours. After cooling, the reaction solution was concentrated under reduced pressure to obtain 5-(1-azaspiro[3.3]heptane-2-yl)benzo[d]thiazol-62g (2 g), 71.7%.

[0377] MS m / z(ESI):231[M+1]

[0378] Referring to the synthesis method of the fifth step of Example 52, 5-(1-azaspiro[3.3]heptane-2-yl)benzo[d]thiazole 62g (100mg) was used to obtain the title product (R)-N-(6-amino-5-methylpyridin-3-yl)-2-(2-(benzo[d]thiazol-5-yl)-1-azaspiro[3.3]heptane-1-yl)-2-carbonylacetamide 62 (30mg), with a yield of 17.0%.

[0379] MS m / z(ESI):408[M+1]

[0380] Examples 63 to 73 were obtained by referring to the method of Example 62.

[0381]

[0382]

[0383] Embodiment 74

[0384] N-(6-amino-5-methylpyridin-3-yl)-2-(5-(benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octane-2-

[0385] 2-Carboacetamide

[0386]

[0387] first step

[0388] tert-Butyl 5-(Benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octane-2-carboxylate

[0389] 2,5-diazaspiro[3.4]octane-2-carboxylic acid tert-butyl ester 74a (200 mg, 0.94 mmol), 5-bromobenzo[d]thiazole 74b (222 mg, 1.04 mmol), tris(dibenzylideneacetone)dipalladium (86 mg, 0.09 mmol), sodium tert-butoxide (199 mg, 2.07 mmol) and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (59 mg, 0.09 mmol) were dissolved in 5 mL of toluene, and nitrogen was replaced three times. The system was heated to 80°C and stirred for 2 hours. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give tert-butyl 5-(benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octane-2-carboxylate 74c (160 mg) in a yield of 49.2%. MS m / z(ESI):346[M+1]

[0390] Step 2

[0391] 5-(2,5-diazaspiro[3.4]octan-5-yl)benzo[d]thiazole

[0392] 5-(Benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octane-2-carboxylic acid tert-butyl ester 74c (160 mg, 0.46 mmol) was dissolved in 5 mL of dichloromethane, 1 mL of trifluoroacetic acid was added, and the system was stirred at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title product 5-(2,5-diazaspiro[3.4]octane-5-yl)benzo[d]thiazole 74d (120 mg), which was directly used for the next step without purification.

[0393] MS m / z(ESI):246[M+1]

[0394] Step 3

[0395] tert-Butyl (5-(2-(5-(Benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octan-2-yl)-2-oxoacetamido)-3-methylpyridin-2-yl)carbamate

[0396] 5-(2,5-diazaspiro[3.4]octan-5-yl)benzo[d]thiazole 74d (100 mg, 0.41 mmol), 2-((6-((tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)amino)-2-carbonylacetic acid 74e (132 mg, 0.45 mmol, obtained by the known method "WO2022 / 26892"), and (7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (310 mg, 0.82 mmol) were dissolved in 5 mL of N,N-dimethylformamide, nitrogen was replaced three times, N,N-diisopropylethylamine (263 mg, 2.04 mmol) was added, and the system was stirred at 25 ° C for 2 hours. The reaction was quenched with water and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography with eluent System C to give tert-butyl (5-(2-(5-(benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octan-2-yl)-2-oxoacetamido)-3-methylpyridin-2-yl)carbamate 74f (130 mg) in a yield of 61.0%.

[0397] MS m / z(ESI):524[M+1]

[0398] Step 4

[0399] N-(6-amino-5-methylpyridin-3-yl)-2-(5-(benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octane-2-

[0400] 2-Carboacetamide

[0401] Referring to the synthesis method of the fourth step of Example 52, N-(6-amino-5-methylpyridin-3-yl)-2-(5-(benzo[d]thiazol-5-yl)-2,5-diazaspiro[3.4]octan-2-yl)-2-oxoacetamide)-3-methylpyridin-2-yl)carbamic acid tert-butyl ester 74f (130 mg, 0.25 mmol) was obtained, with a yield of 59.0%.

[0402] MS m / z(ESI):423[M+1]

[0403] 1 H NMR(400MHz,DMSO)δ10.36(s,1H),9.19(s,1H),8.11(d,1H),7.91(d,1H),7.58(d,1H),7.30(d,1H),6.119(dd,1H),5 .57(s,2H),5.05(d,1H),4.58(d,1H),4.46(d,1H),3.98(d,1H),3.37(t,2H),2.31(q,2H),1.96(s,3H),1.83(t,2H).

[0404] Examples 75 to 91 were obtained by referring to the method of Example 74.

[0405]

[0406]

[0407]

[0408] Embodiment 92

[0409] N-(6-amino-5-methylpyridin-3-yl)-2-(5-(benzo[d]thiazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)-2-

[0410] Oxoacetamide

[0411]

[0412]

[0413] first step

[0414] 5,6-Dihydro-2H-pyran-3-yl trifluoromethanesulfonate

[0415] Dihydro-2H-pyran-3(4H)-one 92a (2.0 g, 19.98 mmol) was dissolved in 20 mL THF, cooled to -78°C under nitrogen protection, and 1 M LiHMDS tetrahydrofuran solution (21.98 mL, 21.98 mmol) was added, and stirred at -78°C for 1 hour. The reaction solution was heated to 0°C, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethyl)sulfonyl)methanesulfonamide (8.56 g, 23.97 mmol) was added, and the temperature was naturally raised to room temperature and stirred for 1 hour. 50 mL of saturated sodium chloride solution was added to quench the mixture, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (200 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System B to give 5,6-dihydro-2H-pyran-3-yl trifluoromethanesulfonate 92b (2.23 g). Yield: 48.0%.

[0416] MS m / z(ESI):233[M+1]

[0417] Step 2

[0418] 5-(5,6-Dihydro-2H-pyran-3-yl)benzo[d]thiazole

[0419] 5,6-Dihydro-2H-pyran-3-yl trifluoromethanesulfonate 92b (1 g, 4.31 mmol), sodium carbonate (0.914 g, 8.62 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (1.69 g, 6.46 mmol), and tetrakistriphenylphosphine palladium (497 mg, 0.43 mmol) were dissolved in dioxane (15 mL) and water (3 mL) and reacted at 80 °C under nitrogen protection for 12 hours. The reaction solution was filtered, concentrated, and extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (150 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System B to give 5-(5,6-dihydro-2H-pyran-3-yl)benzo[d]thiazole 92d (393 mg) in a yield of 42.0%.

[0420] MS m / z(ESI):218[M+1]

[0421] Step 3

[0422] tert-Butyl (5-(2-chloro-2-oxoacetamido)-3-methylpyridin-2-yl)carbamate

[0423] 2-((6-((tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)amino)-2-oxoacetic acid 92e (1.5 g, 5.08 mmol, synthesized by the known method "Patent WO2022026892A1") was dissolved in DCM (20 mL), oxalyl chloride (645 mg, 5.08 mmol) was added dropwise, and a catalytic amount of DMF (5 drops) was added. The reaction was reacted at room temperature for 1 hour, and the reaction solution was concentrated and dried to give crude tert-butyl (tert-butoxycarbonyl) (5-(2-chloro-2-oxoacetamido)-3-methylpyridin-2-yl) carbamate 92f (1.59 g), with a yield of 100.0%.

[0424] MS m / z(ESI):314[M+1]

[0425] Step 4: tert-butyl (5-(2-(5-(benzo[d]thiazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)-2-oxoacetamido)-3-

[0426] methylpyridin-2-yl)carbamate

[0427] Tert-butyl (tert-butoxycarbonyl)(5-(2-chloro-2-oxoacetamido)-3-methylpyridin-2-yl)carbamate 92f (500 mg, 1.59 mmol) and triethylamine (481.8 mg, 4.77 mmol) were dissolved in dichloroethane (8 mL). The mixture was reacted at 20°C for 2 hours under nitrogen protection. The reaction solution was concentrated and the residue was purified by silica gel column chromatography using eluent system B to obtain tert-butyl (5-(2-(5-(5-(benzo[d]thiazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)-2-oxoacetamido)-3-methylpyridin-2-yl)carbamate 92g (418.8 mg) in a yield of 53.3%.

[0428] MS m / z(ESI):595[M+1]

[0429] Step 5

[0430] N-(6-amino-5-methylpyridin-3-yl)-2-(2R,5S)-(5-(benzo[d]thiazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)-2-oxoacetamide

[0431] 92 g (363 mg, 0.61 mmol) of tert-butyl (5-(2-(5-(5-(benzo[d]thiazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)-2-oxoacetamido)-3-methylpyridin-2-yl)carbamate was dissolved in DCM (5 mL), and TFA (2 mL) was added dropwise. The reaction solution was reacted at 20° C. for 2 hours. The reaction solution was concentrated and the residue was purified by silica gel column chromatography using eluent system A to give N-(6-amino-5-methylpyridin-3-yl)-2H-pyran-4-yl)carbamate. -(5-(Benzo[d]thiazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)-2-oxoacetamide 92 (130 mg), yield: 54.0%. The compound was separated by chiral SFC to give N-(6-amino-5-methylpyridin-3-yl)-2-(2R,5S)-2-benzo[c][1,2,5]thiadiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide 92-1 (60.00 mg), yield: 18.6%, dr value: 98%.

[0432] MS m / z(ESI):395[M+1]

[0433] Examples 93-96, 115-116, 118, 120-123 were obtained by referring to the method of Example 92.

[0434]

[0435]

[0436]

[0437]

[0438]

[0439] Embodiment 99

[0440] N-(4-amino-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-carbonylacetamide

[0441]

[0442] first step

[0443] 5-Bromo-N 2 -(4-Methoxybenzyl)-3-nitropyridine-2,4-diamine

[0444] 5-Bromo-2-chloro-3-nitro-pyridin-4-amine 1a (5 g, 19.81 mmol) was dissolved in n-butanol (70 mL), p-methoxybenzylamine (4.08 g, 29.71 mmol, 3.88 mL) and triethylamine (4.01 g, 39.61 mmol, 5.52 mL) were added, nitrogen was replaced three times, and the system was heated to 100 ° C for two hours. Cool to room temperature, concentrate, add water to dissolve, extract with ethyl acetate (150 mL × 3), combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate to obtain the title product 5-bromo-N 2 -(4-methoxybenzyl)-3-nitropyridine-2,4-diamine 1b (7.20 g, crude product).

[0445] MS m / z(ESI):354[M+1]

[0446] Step 2

[0447] 7-Bromo-4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridine-3-oxide

[0448] 5-Bromo-N2-(4-methoxybenzyl)-3-nitropyridine-2,4-diamine 1b (3 g, 8.49 mmol) and iodophenyldiacetic acid (4.10 g, 12.74 mmol) were dissolved in toluene (30 mL), nitrogen was replaced three times, and the system was heated to 80 ° C for two hours. Cool to room temperature, concentrate, add ethyl acetate and water to dissolve, extract with ethyl acetate (100 mL x3), combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate to obtain the title product 7-bromo-4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridine-3-oxide 1c (2.80 g crude product).

[0449] MS m / z(ESI):352[M+1]

[0450] Step 3

[0451] 7-Bromo-N-(4-methoxybenzyl)-[1,2,5]oxadiazolo[3,4-c]pyridin-4-amine

[0452] 7-Bromo-4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridine-3-oxide 1c (3 g, 8.54 mmol) and triphenylphosphine (4.48 g, 17.09 mmol) were dissolved in toluene (50 mL), nitrogen was replaced three times, and the system was heated to 110 ° C for 4 hours. Cool to room temperature, concentrate, add water to dissolve, extract with ethyl acetate (100 mL x 3), combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 7-bromo-N-(4-methoxybenzyl)-[1,2,5]oxadiazolo[3,4-c]pyridine-4-amine 1d (0.32 g) in a yield of 11.2%.

[0453] MS m / z(ESI):336[M+1]

[0454] Step 4

[0455] tert-Butyl (4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)carbamate

[0456] 7-Bromo-N-(4-methoxybenzyl)-[1,2,5]oxadiazolo[3,4-c]pyridine-4-amine 1d (0.32 g, 0.95 mmol), tris[dibenzylideneacetone]dipalladium (92 mg, 0.10 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (116 mg, 0.20 mmol), tert-butyl carbamate (199 mg, 1.70 mmol) and sodium tert-butoxide (274 mg, 2.85 mmol) were dispersed in toluene (20 mL), and the system was heated to 100 ° C and stirred for 12 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, dissolved in 30 mL of water, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product (4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)carbamic acid tert-butyl ester 1e (0.30 g), yield: 84.9%. MS m / z (ESI): 372 [M+1]

[0457] Step 5

[0458] N 4 -(4-methoxybenzyl)-[1,2,5]oxadiazolo[3,4-c]pyridine-4,7-diamine

[0459] Tert-butyl (4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)carbamate 1e (0.30 g, 0.81 mmol) and trifluoroacetic acid (620 μL, 8.10 mmol) were dissolved in dichloromethane (20 mL) and stirred at 20° C. for 12 hours. The reaction solution was concentrated under reduced pressure to obtain the title product N 4 -(4-methoxybenzyl)-[1,2,5]oxadiazolo[3,4-c]pyridine-4,7-diamine 1e (0.22 g), yield: 100%.

[0460] MS m / z(ESI):272[M+1]

[0461] Step 6

[0462] 2-((4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)amino)-2-oxoacetic acid

[0463] N 4 -(4-methoxybenzyl)-[1,2,5]oxadiazolo[3,4-c]pyridine-4,7-diamine 1e (0.22 g, 0.81 mmol) was dissolved in 10 mL of tetrahydrofuran, sodium hydride (65 mg, 1.62 mmol, 60%) was added at 0°C, stirred at 0°C for 1 h, and then oxalyl chloride (206 μL, 2.43 mmol) was added at 0°C, stirred at 20°C for 12 hours. 1 mL of water was added to the reaction solution to quench, concentrated under reduced pressure, extracted with ethyl acetate (20 mL×2), the organic phases were combined and concentrated under reduced pressure to obtain the title product 2-((4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)amino)-2-oxoacetic acid 1f as a crude product (0.22 g), which was directly used in the next step without separation and purification.

[0464] MS m / z(ESI):344[M+1]

[0465] Referring to the synthesis method of the third step to the fourth step of Example 1, N-(4-amino-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)-2-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-carbonylacetamide (0.16 g) was obtained by the crude product (0.22 g, 0.64 mmol) of 2-((4-((4-methoxybenzyl)amino)-[1,2,5]oxadiazolo[3,4-c]pyridin-7-yl)amino)-2-oxoacetic acid 1f with a yield of 56.5%.

[0466] MS m / z(ESI):438[M+1]

[0467] Embodiment 112

[0468] 5-(6-amino-5-methylpyridin-3-yl)-1H-imidazol-2-yl)2-(benzothiazol-5-yl)-5-methylpiperidin-1-yl)methanone

[0469]

[0470] first step

[0471] 5-(6-Amino-5-methylpyridin-3-yl)-1H-imidazole-2-carboxylic acid methyl ester

[0472] 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 112a (120 mg, 0.51 mmol), 5-bromo-1H-imidazole-2-carboxylic acid methyl ester 112b (84 mg, 0.41 mmol), cesium carbonate (510 mg, 1.57 mmol), and bis(diphenylphosphino)ferrocene]dichloropalladium (150 mg, 0.20 mmol) were dissolved in dioxane (6 mL) and water (1.5 mL), and the reaction was stirred in a microwave at 150° C. for 0.5 hour. The reaction solution was cooled to room temperature, 30 ml of ethyl acetate was added, washed with water (30 mL) and saturated sodium chloride solution (100 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System B to give 5-(6-amino-5-methylpyridin-3-yl)-1H-imidazole-2-yl)-2-(thiazol-5-yl)-5-methylpiperidin-1-yl)methanone 112c (60 mg) in a yield of 50.1%.

[0473] MS m / z(ESI):233[M+1]

[0474] Step 2

[0475] 5-(6-Amino-5-methylpyridin-3-yl)-1H-imidazole-2-carboxylic acid

[0476] 5-(6-amino-5-methylpyridin-3-yl)-1H-imidazole-2-carboxylic acid methyl ester 112c (60 mg, 0.26 mmol) was dissolved in 5 mL of methanol, and 1 mL of sodium hydroxide (52 mg, 1.29 mmol) was added under ice bath, and the system was stirred at 45°C for 12 hours. The reaction solution was cooled to room temperature, concentrated, extracted with dichloromethane (50 mL), washed with water (100 mL) and saturated sodium chloride solution (100 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give 5-(6-amino-5-methylpyridin-3-yl)-1H-imidazole-2-carboxylic acid 4 (35 mg) in a yield of 62.1%.

[0477] MS m / z(ESI):219[M+1]

[0478] Step 3

[0479] 5-(6-amino-5-methylpyridin-3-yl)-1H-imidazol-2-yl)2-(benzothiazol-5-yl)-5-methylpiperidin-1-yl)methanone

[0480] 5-(6-Amino-5-methylpyridin-3-yl)-1H-imidazole-2-carboxylic acid 112d (35 mg, 0.16 mmol), 5-(5-methylpiperidin-2-yl)benzothiazole 112e (37 mg, 0.16 mmol, synthesized by the known method "WO2022026892A1"), HATU (73 mg, 0.19 mmol), and DIPEA (83 mg, 0.64 mmol) were dissolved in 3 mL of N,N-dimethylformamide and the reaction was stirred at 45 °C for 12 hours. The reaction solution was cooled to room temperature, 30 ml of ethyl acetate was added, washed with water (30 mL) and saturated sodium chloride solution (30 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System B to give 5-(6-amino-5-methylpyridin-3-yl)-1H-imidazole-2-yl)-2-(benzothiazol-5-yl)-5-methylpiperidin-1-yl)methanone (8 mg), yield: 11.6%.

[0481] MS m / z(ESI):433[M+1]

[0482] Embodiment 113

[0483] rac-2-((6-amino-5-methylpyridin-3-yl)amino)-1-((2R,5S)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)ethan-1-one

[0484]

[0485] first step

[0486] 6-(N,N-di-tert-butoxycarbonyl imide)-5-methylpyridine-3-glycine acid ethyl ester

[0487] N-(5-amino-6-methyl-2-pyridyl)-N-tert-butoxycarbonyl-carbamic acid tert-butyl ester 113a (2 g, 6.18 mmol, synthesized by the known method "Patent WO2022026892A1") was dissolved in 20 ml of acetonitrile, cesium carbonate (3 g, 9.21 mmol) and ethyl chloroacetate (1 g, 8.16 mmol) were added, and the reaction was carried out at 80°C for 12 hours. The reaction solution was cooled, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain 6-(N-tert-butoxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridine-3-glycine ethyl ester 113b (200 mg), with a yield of 7.90%.

[0488] MS m / z(ESI):410[M+1]

[0489] Step 2

[0490] 6-(N-tert-Butyloxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridine-3-glycine ethyl ester

[0491] 6-(N-tert-Butyloxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridine-3-glycine ethyl ester 113b (200 mg, 0.49 mmol) was dissolved in a mixed solvent of 10 ml tetrahydrofuran and 2 ml water, and sodium hydroxide (200 mg, 5.0 mmol) was added, and the mixture was stirred at 20° C. for 2 hours. The reaction solution was cooled and concentrated under reduced pressure to obtain 6-(N-tert-Butyloxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridine-3-glycine acetic acid 113c (100 mg), with a yield of 53.7%.

[0492] MS m / z(ESI):382[M+1]

[0493] Step 3

[0494] 2-(6-(N-tert-Butyloxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridin-3-yl)amino)-1-(2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)ethan-1-one

[0495] 6-(N-tert-Butyloxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridine-3-glycine acetate 113c (100 mg, 0.26 mmol) and 5-(5-methylpiperidin-2-yl)benzo[d]thiazole (100 mg, 0.43 mmol, synthesized by the known method "Patent WO2022026892A1") were dissolved in 10 ml of dichloromethane, and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (125 mg, 0.33 mmol) and triethylamine (100 mg, 0.99 mmol) were added, and the reaction was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, quenched by adding 50 mL of saturated ammonium chloride solution, extracted with ethyl acetate (50 mL×3), and the organic phases were combined, washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (20 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to give 2-(6-(N-tert-butoxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridin-3-yl)amino)-1-(2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)ethane-1-one 113d (40 mg), yield: 25.6%.

[0496] MS m / z(ESI):596[M+1]

[0497] Step 4

[0498] 2-((6-amino-5-methylpyridin-3-yl)amino)-1-(2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)ethyl-1-one

[0499] 2-(6-(N-tert-butyloxycarbonyl-carbamic acid tert-butyl ester)-5-methylpyridin-3-yl)amino)-1-(2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)ethane-1-one 113d (40 mg, 0.067 mmol) was dissolved in 10 ml of trifluoroacetic acid and stirred at 20°C for 12 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent system C to give 2-((6-amino-5-methylpyridin-3-yl)amino)-1-(2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)ethyl-1-one 113 (6 mg) in a yield of 22.6%.

[0500] MS m / z(ESI):396[M+1]

[0501] 1H NMR (400MHz, DMSO) δ9.40(s,1H),8.18(s,1H),8.14(d,1H),7.93(s,1H),7.36(d,1H),7.32(s,1H),6.80(s,1H),4. 88(s,2H),4.06(d,1H),3.79(s,2H),2.25(d,2H),1.98(s,3H),1.89(s,2H),1.69(s,2H),1.33(s,1H),1.02(s,3H).

[0502] Embodiment 117

[0503] N-(6-amino-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetamide

[0504]

[0505] first step

[0506] 2-(5-methyl-2-oxopiperidin-1-yl)-2-oxoacetic acid ethyl ester

[0507] 5-Methylpiperidin-2-one 117a (3.8 g, 33.63 mmol) was dispersed in 50 mL of tetrahydrofuran, sodium hydrogen hydrate (1.6 g, 40 mmol, 60 wt%) was added at 0°C, and the mixture was stirred at 0°C for 1 hour. Ethyl oxalyl chloride 117b (6.8 g, 50 mmol) was added, and the mixture was stirred at 25°C for 16 hours. 10 mL of water was added to quench the mixture, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title product ethyl 2-(5-methyl-2-oxopiperidin-1-yl)-2-oxoacetate 117c (4 g), with a yield of 55.6%.

[0508] MS m / z(ESI):214[M+1]

[0509] Step 2

[0510] Ethyl 2-(3-methyl-6-(trifluoromethanesulfonyloxy)-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetate

[0511] 2-(5-methyl-2-oxopiperidin-1-yl)-2-oxoacetic acid ethyl ester 117c (2 g, 9.39 mmol) was dispersed in 50 mL of tetrahydrofuran, and lithium diisopropylamide (5 mL, 10 mmol, 2M / L tetrahydrofuran solution) was added dropwise at -78°C, and the mixture was stirred at 78°C for 1 hour. Trifluoromethanesulfonic acid anhydride (2.82 g, 10 mmol) was added dropwise at -78°C, and the mixture was stirred at 78°C for 1 hour. 20 mL of water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (30 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title product 2-(3-methyl-6-(trifluoromethanesulfonyloxy)-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetic acid ethyl ester 117d (700 mg), with a yield of 21.5%.

[0512] MS m / z(ESI):346[M+1]

[0513] Step 3

[0514] 2-(6-(Benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetic acid

[0515] Ethyl 2-(3-methyl-6-(trifluoromethanesulfonyloxy)-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetate 117d (700 mg, 2.03 mmol), 5-benzothiazolyl pinacol borate (783 mg, 3 mmol), tetrakis(triphenylphosphine)palladium (115 mg, 0.10 mmol) and sodium carbonate (848 mg, 8 mmol) were dispersed in 10 mL of tetrahydrofuran and 2 mL of water and stirred at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent system A to give the title product 2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetic acid 117e (300 mg) in a yield of 48.9%.

[0516] MS m / z(ESI):303[M+1]

[0517] Step 4

[0518] N-(6-(N′,N′-di(tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetamide

[0519] 2-(6-(Benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetic acid 117e (300 mg, 0.99 mmol), 1,3-bis(1,1-dimethylethyl)2-(5-amino-3-methyl-2-pyridyl)imide dicarbonate 117f (388 mg, 1.2 mmol, synthesized by the known method "Patent IN2015KO00722 A"), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate (380 mg, 1 mmol) and N,N-diisopropylethylamine (387 mg, 3 mmol) were dispersed in 10 mL of dichloromethane and stirred at 25°C for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to obtain 117 g (210 mg) of the title product, N-(6-(N′,N′-di(tert-butyloxycarbonyl)amino)-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetamide, yield: 34.9%. MS m / z (ESI): 608 [M+1]

[0520] Step 5

[0521] N-(6-amino-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-

[0522] 2-Oxoacetamide

[0523] N-(6-(N′,N′-di(tert-butyloxycarbonyl)amino)-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetamide 117 g (150 mg, 0.25 mmol) was dispersed in 5 mL of trifluoroacetic acid and stirred at 25° C. for 16 hours. The reaction solution was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using eluent system B to give the title product N-(6-amino-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridin-1(2H)-yl)-2-oxoacetamide 117 (38 mg) in a yield of 37.3%.

[0524] MS m / z(ESI):408[M+1]

[0525] 1H NMR(400MHz,DMSO-d6)δ9.72(b,1H),9.31-9.17(m,1H),8.18(s,1H),8.06-7.78(m,2H),7.53-6.92 (m,2H),5.39(b,3H),4.02(s,1H),3.36(dd,1H),2.56-2.50(m,1H),2.20-1.69(m,5H),1.04(d,3H).

[0526] Embodiment 121

[0527] N-(6-amino-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetamide

[0528]

[0529] first step

[0530] (E)-4-(Benzo[d]thiazol-5-yl)-2-oxobut-3-enoic acid

[0531] Benzo[d]thiazole-5-carboxaldehyde 121a (5 g, 30.67 mmol) and pyruvic acid 121b (3.08 g, 35 mmol) were dispersed in 50 mL formic acid, potassium hydroxide (1.74 g, 31 mmol) was added at 0°C, and the reaction was stirred at 40°C for 4 hours. 6N hydrochloric acid was added to adjust the pH to 5. Extraction was performed with ethyl acetate (50 mL×3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title product (E)-4-(benzo[d]thiazole-5-yl)-2-oxobut-3-enoic acid 121c (5.71 g), with a yield of 79.9%. MS m / z (ESI): 234 [M+1]

[0532] Step 2

[0533] 2-(6-(Benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetic acid

[0534] (E)-4-(Benzo[d]thiazol-5-yl)-2-oxobut-3-enoic acid 121c (5 g, 21.46 mmol) and isoprene (6.81 g, 100 mmol) were dispersed in 200 mL of acetonitrile, anhydrous ferric chloride (324 mg, 2 mmol) was added, and the reaction was stirred at 40°C for 16 hours. 50 mL of water was added to quench, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (30 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title product 2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetic acid 121d (415 mg) in a yield of 6.4%.

[0535] MS m / z(ESI):302[M+1]

[0536] Step 3

[0537] N-(6-(N′,N′-di(tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetamide

[0538] 2-(6-(Benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetic acid 121d (300 mg, 0.99 mmol), 1,3-bis(1,1-dimethylethyl)2-(5-amino-3-methyl-2-pyridyl)imide dicarbonate 121e (388 mg, 1.2 mmol, synthesized by the known method "Patent IN2015KO00722 A"), N,N,N',N'-tetramethyl-O-(7-azabenzotriazole-1-yl)urea hexafluorophosphate (380 mg, 1 mmol) and N,N-diisopropylethylamine (387 mg, 3 mmol) were dispersed in 10 mL of dichloromethane and stirred at 25°C for 16 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent System A to give the title product, N-(6-(N′,N′-di(tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetamide 121f (165 mg) in a yield of 27.5%.

[0539] MS m / z(ESI):607[M+1]

[0540] Step 4

[0541] N-(6-amino-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetamide

[0542] N-(6-(N′,N′-di(tert-butyloxycarbonyl)amino)-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetamide 121f (150 mg, 0.25 mmol) was dispersed in 5 mL of trifluoroacetic acid and stirred at 25° C. for 16 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent system B to give the title product N-(6-amino-5-methylpyridin-3-yl)-2-(6-(benzo[d]thiazol-5-yl)-3-methylcyclohex-3-en-1-yl)-2-oxoacetamide 121 (38 mg) in a yield of 37.3%.

[0543] MS m / z(ESI):407[M+1]

[0544] 1 H NMR(400MHz,DMSO-d6)δ9.96(s,1H),9.33(s,1H),8.02(d,1H),7.96-7.93(m,2H),7.40(dd,1H),7.37(d, 1H),5.63(s,2H),5.52(s,1H),4.12(td,1H),3.30(td,1H),2.44-2.11(m,4H),1.97(s,3H),1.71(s,3H).

[0545] Embodiment 119

[0546] N 1 -(6-amino-5-methylpyridin-3-yl)-N 2 -Methyl-N 2 -(2-(Trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-

[0547] b]pyridin-5-yl)oxyaldehyde amide

[0548]

[0549] Reference Example 1 The synthesis method of the third step to the fourth step was obtained by 2-((6-((tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)amino)-2-carbonylacetic acid 74e (75 mg, 0.25 mmol, obtained by a known method "WO2022 / 26892") and N-methyl-2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridine-5-amine (59 mg, 0.25 mmol, obtained by a known method "WO2022 / 169948") to obtain N 1 -(6-amino-5-methylpyridin-3-yl)-N 2 -Methyl-N 2 -(2-(Trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-yl)oxyaldehyde amide 119 (10 mg), yield: 9.6%.

[0550] MS m / z(ESI):410[M+1]

[0551] 1 H NMR(400MHz,DMSO)δ10.26(d,1H),8.07-7.84(m,2H),7.77(t,1H),7.47-7.41(m,1H),5.33(s,2H),5 .22(s,1H),4.79(d,1H),4.65(t,1H),4.12-4.00(m,2H),2.80(s,1.5H),2.62(s,1.5H),1.98(d,3H).

[0552] Embodiment 124

[0553] (E)-3-((6-amino-5-methylpyridin-3-yl)methylene)-1-(benzo[d]thiazol-5-ylmethyl)piperidin-2-one

[0554] first step

[0555] Benzo[d]thiazol-5-ylmethanol

[0556] Benzo[d]thiazole-5-carboxylic acid ethyl ester 124a (1 g, 4.83 mmol) was dissolved in 20 ml of tetrahydrofuran, cooled to -60°C, and diisobutylaluminum hydride (5 ml, 10 mmol, 2 M) was added at -60°C, and the reaction was stirred at 25°C for 12 hours. After cooling, 5 mL of saturated ammonium chloride solution was added to quench, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (20 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give benzo[d]thiazol-5-ylmethanol 124b (500 mg) in a yield of 62.7%.

[0557] MS m / z(ESI):166[M+1]

[0558] Step 2

[0559] 5-(Chloromethyl)benzo[d]thiazole

[0560] Benzo[d]thiazol-5-ylmethanol 124b (500 mg, 3.03 mmol) was dissolved in 10 ml of dichloromethane, and dichlorothionyl (1 g, 8.405 mmol) was added, and the mixture was stirred at 25°C for 2 hours. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to give 5-(chloromethyl)benzo[d]thiazole 124c (400 mg) in a yield of 72.0%.

[0561] MS m / z(ESI):184[M+1]

[0562] Step 3

[0563] 2-Carbonylpiperidine-1-carboxylic acid tert-butyl ester

[0564] Piperidin-2-one 124d (5 g, 50.44 mmol) was dissolved in 50 ml of dichloromethane, and triethylamine (10 g, 98.92 mmol), di-tert-butyl dicarbonate (15 g, 68.73 mmol) and 4,4-dimethylaminopyridine (500 mg, 4.093 mmol) were added, and the mixture was stirred at 25°C for 2 hours. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain tert-butyl 2-carbonylpiperidine-1-carboxylate 124e (8 g) in a yield of 79.6%.

[0565] MS m / z(ESI):144[M-55]

[0566] Step 4

[0567] 5-Bromo-2-chloro-3-methylpyridine

[0568] 5-Bromo-3-methylpyridin-2(1H)-one 124f (5 g, 26.59 mmol) was dissolved in 50 ml of phosphorus oxychloride and stirred at 100°C for 12 hours. After cooling, the reaction solution was concentrated under reduced pressure, quenched by adding 50 mL of saturated ammonium chloride solution, extracted with ethyl acetate (50 mL×3), and the organic phases were combined, washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (20 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent system A to obtain 5-bromo-2-chloro-3-methylpyridine 124g (4 g) with a yield of 72.8%.

[0569] MS m / z(ESI):206[M+1]

[0570] Step 5

[0571] 6-Chloro-5-methylnicotinaldehyde

[0572] 124g (4g, 19.37mmol) of 5-bromo-2-chloro-3-methylpyridine was dissolved in 50ml of tetrahydrofuran and condensed to 0°C. Isopropylmagnesium chloride (15ml, 30mmol, 2M) was added at 0°C and stirred for 1 hour at 0°C. N-formylmorpholine (3g, 26.06mmol) was added and stirred for 2 hours at 0°C. The reaction solution was concentrated under reduced pressure and quenched by adding 50mL of saturated ammonium chloride solution. The reaction solution was extracted with ethyl acetate (50mL×3). The organic phases were combined, washed with saturated sodium bicarbonate solution (10mL) and saturated sodium chloride solution (20mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain 6-chloro-5-methylnicotinaldehyde 124h (2g) with a yield of 66.4%.

[0573] MS m / z(ESI):156[M+1]

[0574] Step 6

[0575] (E)-3-((6-chloro-5-methylpyridin-3-yl)methylene)piperidin-2-one

[0576] 6-Chloro-5-methylnicotinaldehyde 124h (250 mg, 1.61 mmol) was dissolved in 10 ml of tetrahydrofuran and cooled to 0°C. Sodium hydride (250 mg, 12.5 mmol, 60%) and tert-butyl 2-carbonylpiperidine-1-carboxylate 124e (400 mg, 2.008 mmol) were added at 0°C, and the mixture was stirred at 50°C for 12 hours. The reaction solution was concentrated under reduced pressure, quenched by adding 50 mL of saturated ammonium chloride solution, and extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (20 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give (E)-3-((6-chloro-5-methylpyridin-3-yl)methylene)piperidin-2-one 124i (300 mg) in a yield of 78.7%.

[0577] MS m / z(ESI):237[M+1]

[0578] Step 7

[0579] (E)-1-(Benzo[d]thiazol-5-ylmethyl)-3-((6-chloro-5-methylpyridin-3-yl)methylene)piperidin-2-one

[0580] (E)-3-((6-chloro-5-methylpyridin-3-yl)methylene)piperidin-2-one 124i (200 mg, 0.85 mmol) was dissolved in 10 ml of tetrahydrofuran, and sodium hydride (100 mg, 2.5 mmol, 60%) and 5-(chloromethyl)benzo[d]thiazole 124c (200 mg, 1.09 mmol) were added. The reaction was stirred at 50° C. for 12 hours. The reaction solution was concentrated under reduced pressure, quenched by adding 50 mL of saturated ammonium chloride solution, and then the mixture was heated to 40 ℃ for 12 hours. The mixture was extracted with ester (50 mL×3), and the organic phases were combined and washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (20 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to give (E)-1-(benzo[d]thiazol-5-ylmethyl)-3-((6-chloro-5-methylpyridin-3-yl)methylene)piperidin-2-one 124j (100 mg), yield: 30.8%.

[0581] MS m / z(ESI):384[M+1]

[0582] Step 8 (E)-1-(Benzo[d]thiazol-5-ylmethyl)-3-((6-((4-methoxybenzyl)amino)-5-methylpyridin-3-yl)methylene)piperidin-2-one

[0583] (E)-1-(Benzo[d]thiazol-5-ylmethyl)-3-((6-chloro-5-methylpyridin-3-yl)methylene)piperidin-2-one 124j (100 mg, 0.26 mmol) was dissolved in 10 ml of dioxane, and cesium carbonate (250 mg, 0.77 mmol), 4-methoxybenzylamine (100 mg, 0.73 mmol), tris(dibenzylideneacetone)dipalladium (50 mg, 0.10 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (70 mg, 0.12 mmol) were added, and the mixture was stirred at 100° C. for 12 hours. The reaction solution was concentrated under reduced pressure and quenched by adding 50 mL of saturated ammonium chloride solution. The product was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (20 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give (E)-1-(benzo[d]thiazol-5-ylmethyl)-3-((6-((4-methoxybenzyl)amino)-5-methylpyridin-3-yl)methylene)piperidin-2-one 124k (80 mg) in a yield of 63.4%.

[0584] MS m / z(ESI):485[M+1]

[0585] Step 9

[0586] (E)-3-((6-amino-5-methylpyridin-3-yl)methylene)-1-(benzo[d]thiazol-5-ylmethyl)piperidin-2-one

[0587] (E)-1-(Benzo[d]thiazol-5-ylmethyl)-3-((6-((4-methoxybenzyl)amino)-5-methylpyridin-3-yl)methylene)piperidin-2-one 124k (80 mg, 0.16 mmol) was dissolved in 10 ml of trifluoroacetic acid and stirred at 20°C for 12 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent System C to give (E)-3-((6-amino-5-methylpyridin-3-yl)methylene)-1-(benzo[d]thiazol-5-ylmethyl)piperidin-2-one 124k (10 mg) in a yield of 16.6%.

[0588] MS m / z(ESI):365[M+1]

[0589] 1H NMR(400MHz,CD3OD)δ9.25(s,1H),8.36(s,1H),8.06(d,1H),8.00(d,1H),7.91(d,1H),7.60(d, 1H),7.53(d,1H),5.47(s,2H),3.52-3.42(m,2H),2.91-2.79(m,2H),2.17(s,3H),1.89(p,2H).

[0590] Embodiment 125

[0591] (Z)-2-((6-amino-5-methylpyridin-3-yl)methylene)-4-(benzo[d]thiazol-5-ylmethyl)dihydro-2H-pyran-3(4H)-one

[0592]

[0593] Referring to the synthetic method of Example 124, 6-chloro-5-methylnicotinaldehyde 124h (5 g, 42.36 mmol) was used to obtain the title product (Z)-2-((6-amino-5-methylpyridin-3-yl)methylene)-4-(benzo[d]thiazol-5-ylmethyl)dihydro-2H-pyran-3(4H)-one 125 (5 mg) in a yield of 0.05%.

[0594] MS m / z(ESI):367[M+1]

[0595] 1 H NMR(400MHz,DMSO)δ9.42(s,1H),8.16(d,1H),8.11(d,1H),8.02(s,1H),7.82(s,1H),7.4 4(dd,1H),6.61(s,1H),6.50(s,2H),4.81(s,2H),4.23(t,2H),3.57(t,2H),2.08(s,2H).

[0596] Example 126 is obtained by the method of reference Example 125.

[0597]

[0598] Embodiment 127

[0599] 4-Aminomethyl-6-(3-(5-trifluoromethylpyridin-2-yl)morpholine-4-carbonyl)phthalazin-1(2H)-one

[0600] first step

[0601] 1-Benzyloxy-4-chlorophthalazine-6-carbonitrile

[0602] 1-Benzyloxy-6-bromo-4-chlorophthalazine 127a (3 g, 10.14 mmol, synthesized by the known method "Patent WO2022192745"), tetrakistriphenylphosphine palladium (1.17 g, 1.01 mmol) and zinc cyanide (1.19 g, 10.14 mmol) were dissolved in 50 mL of N,N-dimethylformamide and heated and stirred at 120°C for 6 h. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to obtain the title product 1-benzyloxy-4-chlorophthalazine-6-carbonitrile 127b (2.56 g) with a yield of 85.3%.

[0603] MS m / z(ESI):296[M+1]

[0604] Step 2

[0605] 1-Benzyloxy-4-chlorophthalazine-6-carboxylic acid

[0606] 1-Benzyloxy-4-chlorophthalazine-6-carbonitrile 127b (2.56 g, 8.65 mmol) and sodium hydroxide (1.04 g, 26.00 mmol) were dissolved in 20 mL of water, and 2 mL of 30% hydrogen peroxide solution was added, and the mixture was heated and stirred at 100°C for 6 h. The reaction solution was cooled to room temperature, quenched by adding 10 mL of saturated sodium sulfite solution, extracted with ethyl acetate (10 mL×3), and the organic phases were combined, washed with saturated sodium chloride solution (25 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 1-benzyloxy-4-chlorophthalazine-6-carboxylic acid 127c (2.51 g) with a yield of 92.3%.

[0607] MS m / z(ESI):315[M+1]

[0608] Step 3

[0609] 2-(1-Benzyloxy-4-chlorophthalazin-6-yl)(2-(5-trifluoromethylpyridin-2-yl)morpholinyl)methanone

[0610] 1-Benzyloxy-4-chlorophthalazine-6-carboxylic acid 127c (2.51 g, 7.98 mmol), 3-(5-trifluoromethylpyridin-2-yl)morpholine (1.85 g, 7.98 mmol, synthesized by the known method "Patent WO2022132914"), HATU (6.83 g, 16.00 mmol), N,N-diisopropylethylamine (2.07 g, 16.00 mmol) were dissolved in 20 mL of N,N-dimethylformamide and stirred at 20°C for 12 h. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to obtain the title product 2-(1-benzyloxy-4-chlorophthalazine-6-yl)(2-(5-trifluoromethylpyridin-2-yl)morpholinyl)methanone 127d (3.42 g) with a yield of 81.0%.

[0611] MS m / z(ESI):529[M+1]

[0612] Step 4

[0613] 4-Benzyloxy-7-(3-(5-trifluoromethylpyridin-2-yl)morpholinyl-4-formyl)phthalazine-1-carbonitrile

[0614] 2-(1-Benzyloxy-4-chlorophthalazin-6-yl)(2-(5-trifluoromethylpyridin-2-yl)morpholinyl)methanone 127d (3.42 g, 6.46 mmol), zinc cyanide (0.76 g, 6.46 mmol), tris(dibenzylideneacetone)dipalladium (0.60 g, 0.65 mmol), 1,1'-bis(diphenylphosphino)ferrocene (0.36 g, 0.65 mmol) and zinc powder were dispersed in 32 mL of N,N-dimethylformamide and stirred at 100°C for 3 h. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent system B to give the title product 4-benzyloxy-7-(3-(5-trifluoromethylpyridin-2-yl)morpholinyl-4-formyl)phthalazine-1-carbonitrile 127e (2.39 g) in a yield of 71.0%.

[0615] MS m / z(ESI):520[M+1]

[0616] Step 5

[0617] 4-Aminomethyl-6-(3-(5-trifluoromethylpyridin-2-yl)morpholine-4-carbonyl)phthalazin-1(2H)-one

[0618] 4-Benzyloxy-7-(3-(5-trifluoromethylpyridin-2-yl)morpholinyl-4-carbonyl)phthalazine-1-carbonitrile 127e (2.39 g, 4.59 mmol) and hydrochloric acid (12M, 1 mL) were dissolved in 35 mL of methanol, 10% Pd / C (239 mg) was added, the system was replaced with hydrogen atmosphere, and the reaction was stirred at 40°C for 2 h. The reaction solution was cooled, filtered, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title product 4-aminomethyl-6-(3-(5-trifluoromethylpyridin-2-yl)morpholinyl-4-carbonyl)phthalazine-1(2H)-one 127 (1.13 g) in a yield of 56.7%.

[0619] MS m / z(ESI):434[M+1]

[0620] Embodiment 128

[0621] 4-Aminomethyl-6-(1-methyl-5-(5-trifluoromethylpyridin-2-yl)-1H-pyrazol-4-yl)phthalazin-1(2H)-one

[0622] first step

[0623] 2-((7-(1-methyl-5-(5-trifluoromethylpyridin-2-yl)-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)isoindole-1,3-dione

[0624] 2-(4-iodo-1-methyl-1H-pyrazol-5-yl)-5-trifluoromethylpyridine 128a (212 mg, 0.60 mmol, synthesized by the known method "Journal of Medicinal Chemistry, 2017, 60 (13), 5673-5698"), tert-butyl (2-(4-oxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydrophthalazin-1-yl)cyclopropyl)carbamate 128b (259 mg, 0.60 mmol), SPhos-Pd-G2 (86.4 mg, 0.12 mmol) and cesium carbonate (586 mg, 1.80 mmol) were dissolved in a mixed solvent of 5 mL of dioxane and 1 mL of water, replaced with a nitrogen atmosphere, and stirred at 90°C for 3 hours. The reaction mixture was cooled and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System B to give the title product 2-((7-(1-methyl-5-(5-trifluoromethylpyridin-2-yl)-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)isoindole-1,3-dione 128c (194 mg) in a yield of 61.0%.

[0625] MS m / z(ESI):531[M+1]

[0626] Step 2

[0627] 4-Aminomethyl-6-(1-methyl-5-(5-trifluoromethylpyridin-2-yl)-1H-pyrazol-4-yl)phthalazin-1(2H)-one

[0628] 2-((7-(1-methyl-5-(5-trifluoromethylpyridin-2-yl)-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)isoindole-1,3-dione 128c (194 mg, 0.37 mmol) was dissolved in 5 mL of ethanol, 1 mL of 85% hydrazine hydrate was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated, and the residue was purified by reverse phase column chromatography using eluent system C to obtain the title product 4-aminomethyl-6-(1-methyl-5-(5-trifluoromethylpyridin-2-yl)-1H-pyrazol-4-yl)phthalazin-1(2H)-one 128 (65 mg), with a yield of 43.6%.

[0629] MS m / z(ESI):401[M+1]

[0630] Examples 129 to 141 were obtained by referring to the method of Example 128.

[0631]

[0632]

[0633] Embodiment 142

[0634] 4-amino-1-methylpyrazolo[4,3-c]quinolin-8-yl)2-(benzothiazol-5-yl)-5-methylpiperidin-1-yl)methanone

[0635]

[0636] first step

[0637] 1-(3-(4-(Trifluoromethyl)phenyl)morpholine)propyl-2-yn-1-one

[0638] 4-Amino-1-methylpyrazolo[4,3-c]quinoline-8-carboxylic acid 142a (100 mg, 0.41 mmol, synthesized by the known method "WO20220115377A1") and 5-(5-methylpiperidin-2-yl)benzothiazole 142b (96 mg, 0.41 mmol, synthesized by the known method "WO2022026892A1"), HATU (234 mg, 0.62 mmol), DIEA (267 mg, 2.06 mmol) were dispersed in 5 mL of DMF and stirred at 25°C for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to obtain the title product 1-(3-(4-(trifluoromethyl)phenyl)morpholine)propyl-2-yn-1-one 142 (26 mg) in a yield of 13.8%.

[0639] MS m / z(ESI):457[M+1]

[0640] 1H NMR(400MHz,DMSO)δ9.36(s,1H),8.16(s,1H),8.15(d,1H),8.13(d,1H),8.01(s,1H),7.55(d,2H),7.47(dd,1H),7.14(s,2H),5. 56(s,1H),4.06(s,3H),3.13(dd,1H),2.28-2.08(m,2H),1.80(s,1H),1.62(t,1H),1.36-1.25(m,1H),1.16(d,1H),0.98(d,3H).

[0641] Examples 143 to 160 were obtained by referring to the method of Example 142.

[0642]

[0643]

[0644] Embodiment 161

[0645] 4-(Aminomethyl)-6-(5-(benzo[c][1,2,5]oxadiazol-5-yl)-1-methyl-1H-pyrazol-4-yl)phthalazine-1(2H)-

[0646] ketone

[0647]

[0648] first step

[0649] 7-Chloro-1-methyl-1H-pyrazolo[4,3-c]quinolin-4-amine

[0650] 5-Bromo-1-methyl-1H-pyrazole-4-carbonitrile 161a (404 mg, 2.17 mmol), 2-amino-4-chlorophenylboronic acid pinacol ester (500 mg, 1.97 mmol), sodium carbonate (314 mg, 2.96 mmol) and tetrakistriphenylphosphine palladium (228 mg, 0.20 mmol) were dispersed in 6 mL of dioxane and 3 mL of water, and stirred at 100 ° C for 1.5 h under nitrogen. After the reaction, the reaction solution was poured into 50 ml of water, extracted with ethyl acetate (50 mL × 2), and the organic phases were combined, washed with saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title product 7-chloro-1-methyl-1H-pyrazolo[4,3-c]quinolin-4-amine 161b (455 mg) with a yield of 99.3%.

[0651] MS m / z(ESI):233[M+1]

[0652] Step 2

[0653] 5-(2-Amino-4-chlorophenyl)-1-methyl-1H-pyrazole-4-carbonitrile

[0654] 7-Chloro-1-methyl-1H-pyrazolo[4,3-c]quinolin-4-amine 161b (458 mg, 1.97 mmol) and sodium amide (230 mg, 5.91 mmol) were dispersed in 10 mL of toluene and stirred at 90°C for 2 h. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using eluent system B to give the title product 5-(2-amino-4-chlorophenyl)-1-methyl-1H-pyrazole-4-carbonitrile 161c (341 mg) in a yield of 74.5%.

[0655] MS m / z(ESI):233[M+1]

[0656] Step 3

[0657] Di-tert-butyl (7-chloro-1-methyl-1H-pyrazolo[4,3-c]quinolin-4-yl)aminobiscarboxylate

[0658] 5-(2-Amino-4-chlorophenyl)-1-methyl-1H-pyrazole-4-carbonitrile 161c (144 mg, 0.62 mmol), di-tert-butyl dicarbonate (162 mg, 0.74 mmol), 4,4-dimethylaminopyridine (8 mg, 0.07 mmol) and triethylamine (125 mg, 1.24 mmol) were dissolved in 3 mL of dichloromethane and stirred at room temperature for 16 h. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent system B to obtain the title product (7-chloro-1-methyl-1H-pyrazolo[4,3-c]quinolin-4-yl)aminodicarboxylic acid di-tert-butyl ester 161d (236 mg) in a yield of 88.1%.

[0659] MS m / z(ESI):433[M+1]

[0660] Referring to the synthesis method of the second to fourth steps of Example 74, the title product 4-(aminomethyl)-6-(5-(benzo[c][1,2,5]oxadiazol-5-yl)-1-methyl-1H-pyrazol-4-yl)phthalazin-1(2H)-one 161 (9 mg) was obtained by using (7-chloro-1-methyl-1H-pyrazolo[4,3-c]quinolin-4-yl)carbamate 161d (236 mg, 0.55 mmol) in a yield of 3.4%.

[0661] MS m / z(ESI):488[M+1]

[0662] 1 H NMR(400MHz,DMSO)δ8.19(s,1H),8.14(s,1H),8.03(s,1H),7.91(d,1H),7.83( d,1H),7.53(d,1H),6.72(s,2H),4.07(s,3H),3.74(s,3H),0.95-0.80(m,5H).

[0663] Examples 162 to 170 were obtained by referring to the method of Example 161.

[0664]

[0665]

[0666] The following compounds were obtained by referring to the method of the above examples:

[0667]

[0668]

[0669]

[0670]

[0671]

[0672]

[0673]

[0674]

[0675] Biological test evaluation

[0676] The present invention is further described and explained below in conjunction with test examples, but these embodiments are not intended to limit the scope of the present invention.

[0677] Test Example 1: Determination of the inhibitory effect of the compounds of the present invention on the proliferation activity of HCT116 and MTAP Knockout HCT116 cells

[0678] 1.1 Experimental Purpose: The purpose of this test case is to measure the inhibitory effect of compounds on the proliferation activity of HCT116 wild-type and HCT116 MTAP knockout cells.

[0679] 1.2 Experimental instruments:

[0680] Centrifuge (Eppendorf 5810R)

[0681] Microplate reader (BioTek Synergy H1 or PerkinElmer Envision),

[0682] Pipette (Eppendorf or Rainin)

[0683] 1.3 Experimental reagents:

[0684] HCT116 and MTAP Knockout HCT116 cells were purchased from Nanjing Kebai;

[0685] Cell Titer-Glo was purchased from Promega, catalog number G7573;

[0686] McCoy`5A was purchased from Gibco, catalog number 12330031;

[0687] FBS was purchased from Gibco, catalog number 10091148;

[0688] PBS was purchased from Gibco, catalog number 10010023;

[0689] Pancreatin was purchased from Gibco, catalog number 25200056;

[0690] The cell culture plate was purchased from Corning, catalog number 3610.

[0691] 1.4 Experimental methods:

[0692] When HCT116 and MTAP Knockout HCT116 cells were cultured to an appropriate cell density using McCoy'5A medium containing 10% FBS, the cells were collected and adjusted to an appropriate cell concentration using complete medium. The cell suspension was plated on a 96-well plate at 90 μL per well and placed in a 37°C, 5% CO2 incubator to adhere overnight. Compound solutions of different concentrations were prepared using DMSO and culture medium, and a solvent control was set up. The compound solution was added to a 96-well plate at 10 μL per well and placed in a 37°C, 5% CO2 incubator for continued culture for 72 to 240 hours. Then, the CellTiter-Glo solution was added, the plate was shaken to mix evenly, incubated in the dark for 10 to 30 minutes, and read using a Synergy H1 or Envision microplate reader.

[0693] 1.5 Experimental data processing method:

[0694] The inhibition rate was calculated using the luminescence signal value, and the concentration and inhibition rate were fitted with a nonlinear regression curve using Graphpad Prism software to obtain the IC 50 value.

[0695] 1.6 Experimental conclusion:

[0696] The above scheme shows that the compounds of the present invention show about 0.1nM to 100nM (IC 50 ) biological activity; preferably 0.1nM to 50nM (IC 50 ) of biological activity; more preferably 0.1nM to 20nM (IC 50 ) biological activity; most preferably 0.1nM to 10nM (IC 50 )'s biological activity.

[0697] In some embodiments, the IC values ​​of the compounds of the present invention for HCT116 cell proliferation activity are 50 Greater than the IC for proliferation activity of HCT116 MTAP knockout cells 50 About 20 times; preferably greater than about 50 times; more preferably greater than about 70 times; and even more preferably greater than about 100 times.

Claims

1. A compound represented by general formula (IA) or (IB), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: M 1 Select from -N- or -CR 3e -; M 2 Selected from C, N or O; preferably C or O; M 3 Selected from C or N; preferably N; Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl or 10-14 membered tricyclic group; L 1 Select from the key, -(CR aa R bb ) n4 -、-C(O)C(O)-、-C(O)C(O)NR cc -、-C(O)(CR aa R bb ) n4 -、-C(O)(CR aa R bb ) n4 NR cc -、-C(O)NR cc (CR aa R bb ) n4 -、-C(O)C(O)NR cc -、-C(O)CR aa =, -C(O)CR aa =CR bb -、-(CR aa R bb ) n4 C(O)NR cc -、-C(O)-C 3-12 Cycloalkyl-, -C(O)-3-12 membered heterocyclic group-, -C(O)-C 6-12 Aryl-, -C(O)-5-12 membered heteroaryl-, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, substituted by one or more substituents; preferably -CR aa R bb -, -C(O)-, -C(O)C(O)-, -C(O)C(O)NR cc -、-C(O)(CR aa R bb )-、-C(O)(CR aa R bb )NR cc -、-C(O)NR cc (CR aa R bb )-、-C(O)C(O)NR cc -, -C(O)CRaa=, -C(O)CRaa=CR bb -、-(CR aa R bb )C(O)NR cc -、-C(O)-C 3-8 Cycloalkyl-, -C(O)-3-8 membered heterocyclic group-, -C(O)-C 6-10 Aryl-, -C(O)-5-10 membered heteroaryl, -C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; Or any two R 2 Linked with its neighboring atoms to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 3a , R 3b , R 3c , R 3d and R 3e are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; or R 3d and R 3e The atoms adjacent to it, R 3c and R 3d The atoms adjacent to it, R 3b and R 3c The adjacent atoms or R 3a and R 3b Each of its neighboring atoms independently links to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 11a is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 11b is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -OR c 、-NR c R d 、-C(O)R c 、-C(O)NR c R d or -P(O)R c R d , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R a , R b , R c and R d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; or R aa and R bb Linked with its neighboring atoms to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl, one or more substituents; preferably forming C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; x is selected from 0, 1, 2, 3, 4, 5 or 6; y is selected from 0, 1, 2, 3, 4, 5 or 6; and n4 is selected from 0, 1 or 2; Preferably, further as shown in general formula (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (II-I) or (II-J): Ring F is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; preferably C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 aryl and 5-8 membered heteroaryl; more preferably cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl, thienyl, tetrazolyl, triazolyl, R 7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group or C 6-12 Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; q is selected from 0, 1, 2, 3, 4, 5 or 6.

2. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that Further as shown in general formula (VIII): Ring A is selected from 10-14 membered tricyclic groups; R 1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 2a , R 2b , R 2c and R 2d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl, 5-12 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -OR a 、-NR a R b 、-C(O)R a 、-C(O)NR a R b or -P(O)R a R b , the amino group, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R 13 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group or C 6-12 Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; R a and R b are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, thio, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl; x is selected from 0, 1, 2, 3, 4, 5 or 6; and v is selected from 0, 1, 2, 3, 4, 5 or 6.

3. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that Ring A is selected from a 5-8 membered saturated or unsaturated monocyclic heterocyclic group, a phenyl group or a 5-6 membered heteroaryl group; preferably a phenyl group, a pyridyl group, a pyrimidyl group, a pyridazinyl group or a pyrazinyl group.

4. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that Ring A is selected from benzoC 5-8 Cycloalkyl, benzo 5-8 membered heterocyclic group, benzo 5-8 membered heteroaryl, 5-8 membered heteroaryl and C 5-8 Cycloalkyl, 5-8 membered heteroaryl and 5-8 membered heterocyclyl or 5-8 membered heteroaryl and 5-8 membered heteroaryl; preferably More preferred 5. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that Ring A is selected from a 10-14 membered tricyclic ring system; preferably M 4 C or N; Ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; Ring C is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; Ring A is further preferably Further optimization 6. The compound according to any one of claims 1 to 5, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that R 1 Selected from hydrogen, deuterium, fluorine, chlorine, bromine, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, -OR a 、-NR a R b or -C(O)NR a R b , the C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally deuterated, halogenated, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, thio, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 The aryl group and the 5-10 membered heteroaryl group are substituted by one or more substituents; preferably methyl, ethyl, difluoromethyl, trifluoromethyl, amino, -CH 2 NH 2 、-CH 2 NHCH 3 、-CH 2 NHCH 2 CH 3 、-CH 2 OH, -C(O)NH 2 ; R a and R b As defined in any preceding claim.

7. A compound according to any one of claims 1 to 6, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, It is characterized in that The compound structure is as follows:

8. A pharmaceutical composition comprising a therapeutically effective dose of a compound as claimed in any one of claims 1 to 7, a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

9. Use of the compound according to any one of claims 1 to 7, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 8 in the preparation of a PRMT5 inhibitor drug.

10. Use of the compound according to any one of claims 1 to 7, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 8 in the preparation of a drug for treating cancer; wherein the cancer is MTAP-related cancer; Preferably, the cancer is selected from lung cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, head and neck cancer, glioma, glioblastoma, esophageal cancer, pancreatic cancer, mesothelioma, melanoma, astrocytoma, undifferentiated pleomorphic sarcoma, leukemia, gastric adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, brain cancer, gastric cancer, kidney cancer, endometrial cancer, ovarian tumor, prostate cancer, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, urinary tract cancer, soft tissue cancer, pleural cancer, colorectal cancer, colorectal cancer or bile duct cancer; the lung cancer is selected from non-small cell lung cancer, squamous cell lung carcinoma or adenocarcinoma of the lung; the esophageal cancer is selected from esophageal squamous cell carcinoma or esophageal adenocarcinoma.

Citation Information

Cited By

  • PRMT5 inhibitor and application thereof

    CN119751486A

  • PRMT5 inhibitors and uses thereof

    CN119751486B

  • PRMT5 inhibitors and uses thereof

    US12448388B2

  • PRMT5 inhibitor, and composition and use thereof

    WO2025247178A1

  • Protein modulator, and pharmaceutical composition thereof, use thereof and method therefor

    WO2026118996A1